BRCA2Breast cancer type 2 susceptibility protein
Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR).
UniProt locations Chromosome · Chromosome, telomere · Nucleus · Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
Function
Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) [11, 47, 12, 13, 16, 18, 23, 22, 26, 27, 32, 30, 29, 94, 40, 46, 45]. Facilitates the repair of double-strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange [11, 47, 18, 23, 22, 26, 27, 32, 30, 29, 40, 46]. BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone [47, 27, 46].
RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis [29]. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity [38]. Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability [39].
Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination [39]. Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping [31]. Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over [42].
Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly [45]. Together with NPM1, may also regulate centrosome duplication [33]
Evidence & references
- ECO:0000269 PubMed:11239456 ↗
- ECO:0000269 PubMed:12442171 ↗
- ECO:0000269 PubMed:15115758 ↗
- ECO:0000269 PubMed:15199141 ↗
- ECO:0000269 PubMed:15671039 ↗
- ECO:0000269 PubMed:15937124 ↗
- ECO:0000269 PubMed:17515903 ↗
- ECO:0000269 PubMed:17515904 ↗
- ECO:0000269 PubMed:18317453 ↗
- ECO:0000269 PubMed:19303847 ↗
- ECO:0000269 PubMed:20729832 ↗
- ECO:0000269 PubMed:20729858 ↗
- ECO:0000269 PubMed:20729859 ↗
- ECO:0000269 PubMed:21076401 ↗
- ECO:0000269 PubMed:21084279 ↗
- ECO:0000269 PubMed:21719596 ↗
- ECO:0000269 PubMed:24485656 ↗
- ECO:0000269 PubMed:24896180 ↗
- ECO:0000269 PubMed:26976601 ↗
- ECO:0000269 PubMed:27941124 ↗
- ECO:0000269 PubMed:37499663 ↗
- ECO:0000269 PubMed:37515771 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11239456"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12442171"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15115758"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15199141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15671039"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15937124"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515903"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515904"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18317453"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19303847"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729832"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729858"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729859"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21076401"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21084279"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21719596"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24485656"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24896180"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26976601"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27941124"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "37499663"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "37515771"
}
],
"value": "Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) (PubMed:11239456, PubMed:12442171, PubMed:15115758, PubMed:15199141, PubMed:15671039, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:21719596, PubMed:27941124, PubMed:37499663, PubMed:37515771). Facilitates the repair of double-strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange (PubMed:11239456, PubMed:12442171, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:27941124, PubMed:37499663). BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone (PubMed:12442171, PubMed:19303847, PubMed:37499663). RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis (PubMed:20729859). May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656). Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability (PubMed:24896180). Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180). Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping (PubMed:21076401). Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over (PubMed:26976601). Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly (PubMed:37515771). Together with NPM1, may also regulate centrosome duplication (PubMed:21084279)"
}
],
"commentType": "FUNCTION"
}GO functions & biological processes
GO:0004402 · evidence & context
- ECO:0000314 PMID:9824164 ↗ IDA · UniProt · 20060718qualifier: NOT|enables
GO:0002020 · evidence & context
- ECO:0000353 PMID:15314155 ↗ IPI · UniProt · 20100604qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51784"}]}]
GO:0003690 · evidence & context
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: enables
GO:0003697 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250320qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2219"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
- ECO:0000314 PMID:20729832 ↗ IDA · UniProt · 20101006qualifier: enables
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: enables
GO:0005515 · evidence & context
- ECO:0000353 PMID:10373512 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:10373512 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:10551859 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:11597317 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:12242698 ↗ IPI · UniProt · 20090624qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P38398"}]}]
- ECO:0000353 PMID:12242698 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GKK8"}]}]
- ECO:0000353 PMID:12442171 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:15115758 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9"}]}]
- ECO:0000353 PMID:15800615 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:15930293 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y5V3"}]}]
- ECO:0000353 PMID:15967112 ↗ IPI · UniProt · 20070813qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N1V2"}]}]
- ECO:0000353 PMID:16099937 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P02768"}]}]
- ECO:0000353 PMID:16205630 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:16275750 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N137"}]}]
- ECO:0000353 PMID:17515903 ↗ IPI · UniProt · 20070808qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:17515903 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609-1"}]}]
- ECO:0000353 PMID:17515904 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609-1"}]}]
- ECO:0000353 PMID:17541404 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:17541404 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
- ECO:0000353 PMID:18212739 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9"}]}]
- ECO:0000353 PMID:18212739 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9-2"}]}]
- ECO:0000353 PMID:18264088 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:19303847 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:19423707 ↗ IPI · UniProt · 20101007qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
- ECO:0000353 PMID:19628690 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:20421506 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04637"}]}]
- ECO:0000353 PMID:20729832 ↗ IPI · UniProt · 20101006qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:20729832 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:20729832 ↗ IPI · UniProt · 20101006qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
- ECO:0000353 PMID:20729832 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
- ECO:0000353 PMID:20729859 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:21399666 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:21399666 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9P0W2"}]}]
- ECO:0000353 PMID:21601571 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:21719596 ↗ IPI · UniProt · 20160118qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:22116401 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NTI5"}]}]
- ECO:0000353 PMID:24013206 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
- ECO:0000353 PMID:24981860 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:25282148 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:25585578 ↗ IPI · UniProt · 20151008qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000353 PMID:26833090 ↗ IPI · UniProt · 20210120qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28715"}, {"db": "UniProtKB", "id": "P60896"}, {"db": "UniProtKB", "id": "Q06609"}, {"db": "UniProtKB", "id": "Q86YC2"}]}]
- ECO:0000353 PMID:31242413 ↗ IPI · UniProt · 20200907qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O75031"}]}]
- ECO:0000353 PMID:39009827 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GZQ8"}]}]
- ECO:0000353 PMID:9560268 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
- ECO:0000314 PMID:9774970 ↗ IDA · MGI · 20160830qualifier: enables
- ECO:0000353 PMID:9774970 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P38398"}]}]
All recorded function and process assertions (32)
GO:0005515 · evidence & context
- ECO:0000353 PMID:17420451 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:19369211 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:19609323 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22193777 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:24141787 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:24485656 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:24485656 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y253"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:28319063 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:30410870 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
- ECO:0000353 PMID:34591612 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
GO:0030674 · evidence & context
- ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
- ECO:0000314 PMID:15937124 ↗ IDA · UniProt · 20260224qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
- ECO:0000314 PMID:17515903 ↗ IDA · UniProt · 20260224qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
- ECO:0000314 PMID:17515904 ↗ IDA · UniProt · 20260224qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
- ECO:0000314 PMID:19303847 ↗ IDA · UniProt · 20260224qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
GO:0030674 · evidence & context
- ECO:0000314 PMID:39333100 ↗ IDA · UniProt · 20260310qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "1990918", "relation": "part_of"}]}]
GO:0042802 · evidence & context
- ECO:0000353 PMID:21601571 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
- ECO:0000353 PMID:25282148 ↗ IPI · IntAct · 20260725qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
GO:0043015 · evidence & context
- ECO:0000353 PMID:17286961 ↗ IPI · UniProt · 20070807qualifier: enableswithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P23258"}]}]
GO:0140678 · evidence & context
- ECO:0000314 PMID:37515771 ↗ IDA · UniProt · 20260304qualifier: enablesextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6PIW4", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
GO:0000722 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
GO:0000724 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR015187"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR015525"}]}]
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260528qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT4G00020"}]}, {"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT5G01630"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:109337"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
- ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:15937124 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:17515903 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:17515904 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:19303847 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:20729832 ↗ IDA · UniProt · 20101006qualifier: involved_in
- ECO:0000315 PMID:21719596 ↗ IMP · UniProt · 20160118qualifier: involved_in
- ECO:0000314 PMID:27941124 ↗ IDA · UniProt · 20260226qualifier: involved_in
- ECO:0000314 PMID:28398198 ↗ IDA · ComplexPortal · 20251229qualifier: involved_in
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: involved_in
- ECO:0000314 PMID:37515771 ↗ IDA · UniProt · 20260310qualifier: involved_in
GO:0000730 · evidence & context
- ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:15937124 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:17515903 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:17515904 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:19303847 ↗ IDA · UniProt · 20260224qualifier: involved_in
- ECO:0000314 PMID:27941124 ↗ IDA · UniProt · 20260226qualifier: involved_in
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: involved_in
GO:0000730 · evidence & context
- ECO:0000314 PMID:39333100 ↗ IDA · UniProt · 20260310qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "GO", "id": "1990918", "relation": "part_of"}]}]
GO:0006281 · evidence & context
- ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR015525"}]}]
GO:0006289 · evidence & context
- ECO:0000315 PMID:16845393 ↗ IMP · UniProt · 20070807qualifier: involved_in
GO:0006302 · evidence & context
- ECO:0000315 PMID:16845393 ↗ IMP · UniProt · 20070807qualifier: involved_in
GO:0006310 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028026"}]}]
GO:0006355 · evidence & context
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20220922qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT4G00020"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
GO:0006974 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
- ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224qualifier: involved_in
GO:0007127 · evidence & context
- ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028964"}]}]
GO:0007141 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
GO:0033600 · evidence & context
- ECO:0000314 PMID:15930293 ↗ IDA · UniProt · 20070813qualifier: involved_in
GO:0045893 · evidence & context
- ECO:0000314 PMID:9126734 ↗ IDA · UniProt · 20110118qualifier: involved_in
GO:0051298 · evidence & context
- ECO:0000315 PMID:17286961 ↗ IMP · UniProt · 20110318qualifier: involved_in
GO:0070200 · evidence & context
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: involved_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
GO:0070200 · evidence & context
- ECO:0000314 PMID:21076401 ↗ IDA · BHF-UCL · 20151222qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}]}]
GO:0071479 · evidence & context
- ECO:0000315 PMID:14636569 ↗ IMP · ComplexPortal · 20251229qualifier: involved_in
GO:1990426 · evidence & context
- ECO:0000315 PMID:21076401 ↗ IMP · BHF-UCL · 20151222qualifier: involved_inextensions: [{"connectedXrefs": [{"db": "GO", "id": "0000781", "relation": "occurs_in"}]}]
GO:1990918 · evidence & context
- ECO:0000314 PMID:26976601 ↗ IDA · UniProt · 20260306qualifier: involved_in
- ECO:0000314 PMID:39333100 ↗ IDA · UniProt · 20260310qualifier: involved_in
GO:2000001 · evidence & context
- ECO:0005547 PMID:14636569 ↗ NAS · ComplexPortal · 20251229qualifier: involved_in
Names & Taxonomy
- Recommended name
- Breast cancer type 2 susceptibility protein
- Gene
- BRCA2
- Accession / entry
- P51587 · BRCA2_HUMAN
- Species
- Homo sapiens · NCBI 9606
- Recorded aliases
- FACD · FANCD1 · Fanconi anemia group D1 protein
Full taxonomy & recorded names
Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo
{
"names": {
"recommendedName": {
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "8524414"
}
],
"value": "Breast cancer type 2 susceptibility protein"
}
},
"alternativeNames": [
{
"fullName": {
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "15199141"
}
],
"value": "Fanconi anemia group D1 protein"
}
}
]
},
"genes": [
{
"geneName": {
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "8524414"
},
{
"evidenceCode": "ECO:0000312",
"source": "HGNC",
"id": "HGNC:1101"
}
],
"value": "BRCA2"
},
"synonyms": [
{
"value": "FACD"
},
{
"evidences": [
{
"evidenceCode": "ECO:0000303",
"source": "PubMed",
"id": "15199141"
}
],
"value": "FANCD1"
}
]
}
]
}Subcellular Location
UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.
Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress
Evidence & references
- ECO:0000269 PubMed:11239456 ↗
- ECO:0000269 PubMed:19303847 ↗
- ECO:0000269 PubMed:37499663 ↗
Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress
Evidence & references
- ECO:0000269 PubMed:21076401 ↗
Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress
Evidence & references
- ECO:0000269 PubMed:24013206 ↗
- ECO:0000269 PubMed:26833090 ↗
- ECO:0000305 PubMed:21276791 ↗
Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress
Evidence & references
- ECO:0000269 PubMed:21276791 ↗
Evidence & references
- ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250902qualifier: is_active_inwithFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:109337"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q4GZF5"}]}]
Evidence & references
- ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302qualifier: is_active_in
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0276"}]}]
UniProtKB:P51587 · [{"connectedXrefs": [{"db": "GO", "id": "0000084", "relation": "existence_overlaps"}]}]
Evidence & references
- ECO:0000314 PMID:21076401 ↗ IDA · BHF-UCL · 20151222qualifier: located_inextensions: [{"connectedXrefs": [{"db": "GO", "id": "0000084", "relation": "existence_overlaps"}]}]
All recorded location assertions (20)
Evidence & references
- ECO:0000314 PMID:9774970 ↗ IDA · MGI · 20160830qualifier: located_in
Evidence & references
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
- ECO:0000314 PMID:14636569 ↗ IDA · ComplexPortal · 20251229qualifier: located_in
- ECO:0000314 PMID:17286961 ↗ IDA · UniProt · 20070807qualifier: located_in
- ECO:0005547 PMID:19369211 ↗ NAS · ComplexPortal · 20251229qualifier: located_in
- ECO:0000269 PMID:24013206 ↗ EXP · UniProt · 20250406qualifier: located_in
- ECO:0000314 PMID:26833090 ↗ IDA · UniProt · 20210120qualifier: located_in
- ECO:0000314 PMID:9560268 ↗ IDA · UniProt · 20070807qualifier: located_in
- ECO:0000314 PMID:9774970 ↗ IDA · UniProt · 20070807qualifier: located_in
Evidence & references
- ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5685242 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5685341 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5685838 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5686410 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5686440 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5686469 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5686483 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693539 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693561 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693584 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693589 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693593 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-5693620 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9701199 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9704330 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9704408 TAS · Reactome · 20150326qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9709273 TAS · Reactome · 20130213qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9709571 TAS · Reactome · 20220131qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9709601 TAS · Reactome · 20201216qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9853389 TAS · Reactome · 20150326qualifier: located_in
Evidence & references
- ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0468"}]}]
Evidence & references
- ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
Evidence & references
- ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727qualifier: located_inwithFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0048"}]}]
- ECO:0000314 PMID:17286961 ↗ IDA · UniProt · 20070807qualifier: located_in
- ECO:0000314 PMID:21276791 ↗ IDA · UniProt · 20140220qualifier: located_in
Evidence & references
- ECO:0000304 Reactome:R-HSA-9709268 TAS · Reactome · 20201215qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9709273 TAS · Reactome · 20201211qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9763137 TAS · Reactome · 20201211qualifier: located_in
- ECO:0000304 Reactome:R-HSA-9763200 TAS · Reactome · 20220201qualifier: located_in
Evidence & references
- ECO:0000314 PMID:8589722 ↗ IDA · UniProt · 20070807qualifier: located_in
Evidence & references
- ECO:0000314 PMID:14636569 ↗ IDA · ComplexPortal · 20251229qualifier: part_of
Evidence & references
- ECO:0000314 PMID:26833090 ↗ IDA · UniProt · 20210120qualifier: part_of
- ECO:0000314 PMID:9774970 ↗ IDA · UniProt · 20070809qualifier: part_of
- ECO:0000314 PMID:9774970 ↗ IDA · MGI · 20180219qualifier: part_of
Evidence & references
- ECO:0000314 PMID:15930293 ↗ IDA · UniProt · 20070813qualifier: part_of
Evidence & references
- ECO:0000353 PMID:19369211 ↗ IPI · ComplexPortal · 20251229qualifier: part_of
Membrane topology 0
No annotation is recorded in this UniProt entry.
Disease & Variants
Source annotations; a recorded variant is not automatically a clinical classification.
Breast cancer BC
A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Evidence & references
- ECO:0000269 PubMed:10399947 ↗
- ECO:0000269 PubMed:10978364 ↗
- ECO:0000269 PubMed:11139248 ↗
- ECO:0000269 PubMed:11149425 ↗
- ECO:0000269 PubMed:11241844 ↗
- ECO:0000269 PubMed:11948477 ↗
- ECO:0000269 PubMed:12145750 ↗
- ECO:0000269 PubMed:12373604 ↗
- ECO:0000269 PubMed:12442274 ↗
- ECO:0000269 PubMed:12442275 ↗
- ECO:0000269 PubMed:12569143 ↗
- ECO:0000269 PubMed:12938098 ↗
- ECO:0000269 PubMed:14722926 ↗
- ECO:0000269 PubMed:15026808 ↗
- ECO:0000269 PubMed:15172753 ↗
- ECO:0000269 PubMed:15365993 ↗
- ECO:0000269 PubMed:16793542 ↗
- ECO:0000269 PubMed:17924331 ↗
- ECO:0000269 PubMed:23108138 ↗
- ECO:0000269 PubMed:24013206 ↗
- ECO:0000269 PubMed:29161300 ↗
- ECO:0000269 PubMed:8640237 ↗
- ECO:0000269 PubMed:9150152 ↗
- ECO:0000269 PubMed:9609997 ↗
- ECO:0000269 PubMed:9654203 ↗
- ECO:0000269 PubMed:9971877 ↗
Disease susceptibility is associated with variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Breast cancer",
"diseaseAccession": "DI-02602",
"acronym": "BC",
"description": "A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.",
"diseaseCrossReference": {
"database": "MIM",
"id": "114480"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10399947"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10978364"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11139248"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11149425"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11241844"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11948477"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12145750"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12373604"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12442274"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12442275"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12569143"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12938098"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "14722926"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15026808"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15172753"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15365993"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16793542"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17924331"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23108138"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24013206"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29161300"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8640237"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9150152"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9609997"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9654203"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9971877"
}
]
},
"note": {
"texts": [
{
"value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
}
]
}
}Pancreatic cancer 2 PNCA2
A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Evidence & references
- ECO:0000269 PubMed:9140390 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Pancreatic cancer 2",
"diseaseAccession": "DI-02847",
"acronym": "PNCA2",
"description": "A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.",
"diseaseCrossReference": {
"database": "MIM",
"id": "613347"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9140390"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Breast-ovarian cancer, familial, 2 BROVCA2
A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Evidence & references
- ECO:0000269 PubMed:10584720 ↗
- ECO:0000269 PubMed:11158174 ↗
- ECO:0000269 PubMed:7658781 ↗
- ECO:0000269 PubMed:9150155 ↗
Disease susceptibility is associated with variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Breast-ovarian cancer, familial, 2",
"diseaseAccession": "DI-02603",
"acronym": "BROVCA2",
"description": "A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.",
"diseaseCrossReference": {
"database": "MIM",
"id": "612555"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10584720"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11158174"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "7658781"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "9150155"
}
]
},
"note": {
"texts": [
{
"value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
}
]
}
}Fanconi anemia complementation group D1 FANCD1
A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Evidence & references
- ECO:0000269 PubMed:12065746 ↗
- ECO:0000269 PubMed:14670928 ↗
- ECO:0000269 PubMed:16825431 ↗
- ECO:0000269 PubMed:17924331 ↗
- ECO:0000269 PubMed:21719596 ↗
- ECO:0000269 PubMed:23108138 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Fanconi anemia complementation group D1",
"diseaseAccession": "DI-01601",
"acronym": "FANCD1",
"description": "A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.",
"diseaseCrossReference": {
"database": "MIM",
"id": "605724"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12065746"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "14670928"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16825431"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17924331"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21719596"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "23108138"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Glioma 3 GLM3
Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
Evidence & references
- ECO:0000269 PubMed:15689453 ↗
The disease is caused by variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Glioma 3",
"diseaseAccession": "DI-02629",
"acronym": "GLM3",
"description": "Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.",
"diseaseCrossReference": {
"database": "MIM",
"id": "613029"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15689453"
}
]
},
"note": {
"texts": [
{
"value": "The disease is caused by variants affecting the gene represented in this entry"
}
]
}
}Medulloblastoma MDB
Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.
Evidence & references
- ECO:0000269 PubMed:29753700 ↗
Disease susceptibility is associated with variants affecting the gene represented in this entry
Evidence & references
No separate evidence record is supplied for this statement.
Complete source annotation
{
"commentType": "DISEASE",
"disease": {
"diseaseId": "Medulloblastoma",
"diseaseAccession": "DI-01958",
"acronym": "MDB",
"description": "Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.",
"diseaseCrossReference": {
"database": "MIM",
"id": "155255"
},
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "29753700"
}
]
},
"note": {
"texts": [
{
"value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
}
]
}
}Natural variants 160
Scroll across the table for evidence and actions.
160 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| G25RVAR_028167 | 25 | in BC; abolishes interaction with PALB2; dbSNP:rs80358961 G → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W31CVAR_028168 | 31 | in BC; abolishes interaction with PALB2; dbSNP:rs80359214 W → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W31RVAR_028169 | 31 | in BC; abolishes interaction with PALB2; dbSNP:rs80359182 W → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F32LVAR_005085 | 32 | in BC; dbSNP:rs397508057 and dbSNP:rs1555280339 F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Y42CVAR_020705 | 42 | in BC and ovarian cancer; benign; dbSNP:rs4987046 Y → C | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| K53RVAR_005086 | 53 | in BC; dbSNP:rs397507595 K → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N60SVAR_020706 | 60 | in BC; uncertain significance; dbSNP:rs80358463 N → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T64IVAR_032712 | 64 | in BC; dbSNP:rs397507615 T → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| A75PVAR_005087 | 75 | in dbSNP:rs28897701 A → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F81LVAR_005088 | 81 | in BC; dbSNP:rs80358507 F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N108HVAR_008766 | 108 | in dbSNP:rs80358567 N → H | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| R118HVAR_032713 | 118 | in one patient with esophageal carcinoma; dbSNP:rs80358603 R → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M192TVAR_032714 | 192 | in one patient with pancreatic cancer; dbSNP:rs80358805 M → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P201RVAR_005089 | 201 | in BC; dbSNP:rs397507822 P → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V211AVAR_005090 | 211 | in BC V → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P222SVAR_005091 | 222 | in BC; dbSNP:rs397507873 P → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T225AVAR_032715 | 225 | in one patient with BC; normal RNA expression and splicing; dbSNP:rs80358897 T → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N289HVAR_005092 | 289 | in dbSNP:rs766173 N → H | Experimental evidence 6 publications Evidence & references
| No verified residues in this structure |
| C315SVAR_032716 | 315 | in one patient with esophageal carcinoma; dbSNP:rs79483201 C → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K322QVAR_018908 | 322 | in dbSNP:rs11571640 K → Q | Experimental evidence Evidence & references
| No verified residues in this structure |
| S326RVAR_032717 | 326 | in BC; benign; dbSNP:rs28897706 S → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K327EVAR_008767 | 327 | in BC; uncertain significance; dbSNP:rs80359242 K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V355LVAR_005093 | 355 | in lung cancer V → L | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| N372HVAR_005094 | 372 | in dbSNP:rs144848 N → H | Experimental evidence 9 publications Evidence & references
| No verified residues in this structure |
| G405RVAR_020707 | 405 | in BC; uncertain significance G → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T431IVAR_020708 | 431 | in BC; uncertain significance; dbSNP:rs876660828 T → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R448HVAR_020709 | 448 | in BC; uncertain significance; dbSNP:rs80358423 R → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E462GVAR_020710 | 462 | in BC; benign; dbSNP:rs56403624 E → G | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| I505TVAR_032718 | 505 | in BC; benign; dbSNP:rs28897708 I → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K513RVAR_056751 | 513 | in dbSNP:rs28897709 K → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| C554WVAR_005095 | 554 | in BC; benign; dbSNP:rs80358451 C → W | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T582PVAR_008768 | 582 | in dbSNP:rs80358457 T → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T598AVAR_020711 | 598 | in dbSNP:rs28897710 T → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S599FVAR_035436 | 599 | in dbSNP:rs1046984 S → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P606LVAR_076440 | 606 | in dbSNP:rs80358469 P → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L613RVAR_020712 | 613 | in BC; uncertain significance; dbSNP:rs587780646 L → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T630IVAR_005096 | 630 | in dbSNP:rs80358479 T → I | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| D707YVAR_008769 | 707 | in dbSNP:rs80358487 D → Y | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| D728AVAR_005097 | 728 | in BC; dbSNP:rs757577670 D → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I729MVAR_032719 | 729 | in BC; dbSNP:rs397507620 I → M | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| M784VVAR_008770 | 784 | in dbSNP:rs11571653 M → V | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| N886IVAR_008771 | 886 | in dbSNP:rs80358526 N → I | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| L929SVAR_018909 | 929 | in dbSNP:rs2227943 L → S | Experimental evidence Evidence & references
| No verified residues in this structure |
| D935NVAR_008772 | 935 | in BC; uncertain significance; dbSNP:rs28897716 D → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S976FVAR_018910 | 976 | in dbSNP:rs11571656 S → F | Experimental evidence Evidence & references
| No verified residues in this structure |
| I982LVAR_056752 | 982 | in dbSNP:rs28897717 I → L | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| N987IVAR_018911 | 987 | in dbSNP:rs2227944 N → I | Experimental evidence Evidence & references
| No verified residues in this structure |
| N991DVAR_005098 | 991 | in dbSNP:rs1799944 N → D | Experimental evidence 7 publications Evidence & references
| No verified residues in this structure |
| E1036KVAR_020713 | 1036 | in BC; uncertain significance E → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1106RVAR_020714 | 1106 | in BC; uncertain significance; dbSNP:rs1298550035 S → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N1147SVAR_005099 | 1147 | in dbSNP:rs1799951 N → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1172LVAR_032720 | 1172 | in BC; benign; dbSNP:rs80358600 S → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1179NVAR_020715 | 1179 | in BC; dbSNP:rs397507674 S → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N1279SVAR_020716 | 1279 | in dbSNP:rs1060502384 N → S | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Natural variantVAR_008773 | 1286 | Natural variant | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| C1290YVAR_008774 | 1290 | in dbSNP:rs41293485 C → Y | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Natural variantVAR_005100 | 1302 | in BC | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| T1414MVAR_008775 | 1414 | in dbSNP:rs70953664 T → M | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| D1420YVAR_008776 | 1420 | in dbSNP:rs28897727 D → Y | Experimental evidence 6 publications Evidence & references
| No verified residues in this structure |
| K1445TVAR_020717 | 1445 | in BC; uncertain significance K → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D1513NVAR_008777 | 1513 | in dbSNP:rs80358687 D → N | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| L1522FVAR_032721 | 1522 | in one patient with BC; dbSNP:rs397507729 L → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F1524VVAR_020718 | 1524 | in BC; benign; dbSNP:rs56386506 F → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G1529RVAR_005101 | 1529 | in dbSNP:rs28897728 G → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| V1542MVAR_056753 | 1542 | in dbSNP:rs28897729 V → M | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| H1561NVAR_018912 | 1561 | in dbSNP:rs2219594 H → N | Experimental evidence Evidence & references
| No verified residues in this structure |
| C1580YVAR_020719 | 1580 | in BC; somatic mutation; dbSNP:rs398122784 C → Y | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1593DVAR_008778 | 1593 | in dbSNP:rs80358703 E → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V1643AVAR_056754 | 1643 | in dbSNP:rs28897731 V → A | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| T1679IVAR_020720 | 1679 | in BC T → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K1690NVAR_032722 | 1690 | in BC; benign; dbSNP:rs56087561 K → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N1730YVAR_032723 | 1730 | in BC; dbSNP:rs397507770 N → Y | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G1771DVAR_008779 | 1771 | in BC; benign; dbSNP:rs80358755 G → D | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| V1804AVAR_020721 | 1804 | in BC; dbSNP:rs370252983 V → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N1805SVAR_008780 | 1805 | in dbSNP:rs80358765 N → S | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| N1880KVAR_005102 | 1880 | in dbSNP:rs11571657 N → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T1887MVAR_032724 | 1887 | in BC; dbSNP:rs397507795 T → M | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E1901KVAR_020722 | 1901 | in BC E → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D1902NVAR_008781 | 1902 | in dbSNP:rs4987048 D → N | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| T1915MVAR_005103 | 1915 | in dbSNP:rs4987117 T → M | Experimental evidence 5 publications Evidence & references
| No verified residues in this structure |
| I1929VVAR_020723 | 1929 | in BC; benign; dbSNP:rs79538375 I → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S1979RVAR_056755 | 1979 | in dbSNP:rs28897737 S → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| V1988IVAR_032725 | 1988 | in one patient with esophageal carcinoma; somatic mutation; dbSNP:rs28897739 V → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T2031AVAR_020724 | 2031 | in BC; uncertain significance T → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2034CVAR_005104 | 2034 | in dbSNP:rs1799954 R → C | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| G2044VVAR_032726 | 2044 | in one patient with BC; dbSNP:rs56191579 G → V | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S2072CVAR_020725 | 2072 | in BC; dbSNP:rs80358862 S → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H2074NVAR_008782 | 2074 | in dbSNP:rs34309943 H → N | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| E2089DVAR_008783 | 2089 | in BC E → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Y2094CVAR_020726 | 2094 | in BC; dbSNP:rs397507838 Y → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P2096LVAR_020727 | 2096 | in BC P → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2108CVAR_032727 | 2108 | in dbSNP:rs55794205 R → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H2116RVAR_061563 | 2116 | in dbSNP:rs55953736 H → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| V2118LVAR_020728 | 2118 | in BC; uncertain significance V → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K2128NVAR_020729 | 2128 | in BC; dbSNP:rs397507847 K → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N2135HVAR_032728 | 2135 | in BC; dbSNP:rs80358876 N → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V2138FVAR_008784 | 2138 | in dbSNP:rs11571659 V → F | Experimental evidence Evidence & references
| No verified residues in this structure |
| K2162RVAR_018913 | 2162 | in dbSNP:rs11571660 K → R | Experimental evidence Evidence & references
| No verified residues in this structure |
| Y2222CVAR_032729 | 2222 | in BC; dbSNP:rs397507875 Y → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| D2238EVAR_056756 | 2238 | in dbSNP:rs28897742 D → E | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| G2274VVAR_005105 | 2274 | in BC; dbSNP:rs55712212 G → V | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| E2275GVAR_020730 | 2275 | in BC; uncertain significance E → G | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F2293LVAR_020731 | 2293 | in BC; uncertain significance; dbSNP:rs80358912 and dbSNP:rs1381512588 F → L | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2336HVAR_032730 | 2336 | in FANCD1; affects protein splicing and expression; decreases homologous recombination-mediated DNA repair; dbSNP:rs28897743 R → H | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| R2336QVAR_056757 | 2336 | in dbSNP:rs28897743 R → Q | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| G2353RVAR_020732 | 2353 | in BC; benign; dbSNP:rs80358935 G → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| H2415NVAR_005106 | 2415 | in BC H → N | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Q2421HVAR_005107 | 2421 | in BC Q → H | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| H2440RVAR_018914 | 2440 | no effect on homology-directed repair activity; dbSNP:rs4986860 H → R | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N2447DVAR_056758 | 2447 | in dbSNP:rs4986859 N → D | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Q2456EVAR_032731 | 2456 | in BC; dbSNP:rs397507912 Q → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V2466AVAR_008785 | 2466 | in BC; benign; no effect on homology-directed repair activity; dbSNP:rs169547 V → A | Experimental evidence 7 publications Evidence & references
| No verified residues in this structure |
| L2480VVAR_008786 | 2480 | in dbSNP:rs80358965 L → V | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| R2488KVAR_020733 | 2488 | in BC; uncertain significance; dbSNP:rs80358968 R → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I2490TVAR_008787 | 2490 | no effect on homologous recombination-mediated DNA repair; no effect on interaction with SEM1; dbSNP:rs11571707 I → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2502CVAR_063911 | 2502 | in BC; uncertain significance; dbSNP:rs55716624 R → C | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2502HVAR_008788 | 2502 | in dbSNP:rs56070345 R → H | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| L2510PVAR_032732 | 2510 | in FANCD1; hypersensitive to DNA damage; disrupts interaction with SEM1; decreased homology-directed repair activity; dbSNP:rs80358979 L → P | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| T2515IVAR_008789 | 2515 | in BC; benign; dbSNP:rs28897744 T → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W2626CVAR_032733 | 2626 | in FANCD1; hypersensitive to DNA damage; reduced homology-directed repair activity; no effect on interaction with SEM1; dbSNP:rs80359013 W → C | Experimental evidence 4 publications Evidence & references
| No verified residues in this structure |
| I2627FVAR_063912 | 2627 | in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs80359014 I → F | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| L2653PVAR_063913 | 2653 | in BC; uncertain significance; reduced homology-directed repair activity; dbSNP:rs80359022 L → P | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| R2659KVAR_063914 | 2659 | in BC; uncertain significance; dbSNP:rs80359027 R → K | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| E2663VVAR_063915 | 2663 | in BC; pathogenic; major splicing aberration identified with this mutant; dbSNP:rs80359031 E → V | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| L2686PVAR_056759 | 2686 | in dbSNP:rs28897746 L → P | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| N2706SVAR_020734 | 2706 | in dbSNP:rs80359055 N → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T2722RVAR_018661 | 2722 | in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs80359062 T → R | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| D2723GVAR_063916 | 2723 | in BC; pathogenic; major splicing aberration identified with this mutant; reduced homology-directed repair activity; dbSNP:rs41293513 D → G | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| D2723HVAR_020735 | 2723 | in BC; pathogenic; disrupts interaction with SEM1 promoting interaction with XPO1 and BRCA2 cytoplasmic localization; in heterozygous state promotes RAD51 cytoplasmic localization; reduced homology-directed repair activity; dbSNP:rs41293511 D → H | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| V2728IVAR_020736 | 2728 | in BC; benign; dbSNP:rs28897749 V → I | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| K2729NVAR_020737 | 2729 | in BC; benign; no effect on homologous recombination-mediated DNA repair; no effect on interaction with SEM1; dbSNP:rs80359065 K → N | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| G2748DVAR_063917 | 2748 | in BC; pathogenic; dbSNP:rs80359071 G → D | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| R2787HVAR_008790 | 2787 | in BC; uncertain significance; also found in ovarian cancer; uncertain significance; somatic mutation; small decrease of homology-directed repair activity; dbSNP:rs80359078 R → H | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| L2792PVAR_056760 | 2792 | in BC; uncertain significance; decreased homology-directed repair activity; dbSNP:rs28897751 L → P | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| G2793RVAR_020738 | 2793 | in BC; uncertain significance; decreased homology-directed repair activity; dbSNP:rs80359082 G → R | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| S2835PVAR_018915 | 2835 | in dbSNP:rs11571746 S → P | Experimental evidence Evidence & references
| No verified residues in this structure |
| R2842CVAR_032734 | 2842 | in one patient with esophageal carcinoma; somatic mutation; decreased homology-directed repair activity; dbSNP:rs80359104 R → C | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| E2856AVAR_018916 | 2856 | in BC; uncertain significance; no effect on homology-directed repair activity; dbSNP:rs11571747 E → A | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| I2944FVAR_008791 | 2944 | in dbSNP:rs4987047 I → F | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K2950NVAR_020739 | 2950 | in BC; uncertain significance; dbSNP:rs28897754 K → N | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| A2951TVAR_008792 | 2951 | in BC; benign; no effect on homology-directed repair activity; dbSNP:rs11571769 A → T | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| V2969MVAR_008793 | 2969 | in dbSNP:rs59004709 V → M | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| T3013IVAR_020740 | 3013 | in BC; benign; no effect on homology-directed repair activity; dbSNP:rs28897755 T → I | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| R3052WVAR_063918 | 3052 | in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs45580035 R → W | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| P3063SVAR_020741 | 3063 | in a patient with ovarian cancer; uncertain significance; no effect on homology-directed repair activity; dbSNP:rs80359176 P → S | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| G3076EVAR_020742 | 3076 | in BC; also found in pancreatic cancer; decreased homology-directed repair activity; dbSNP:rs80359187 G → E | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| D3095EVAR_005108 | 3095 | in BC; uncertain significance; reduced homology-directed repair activity; dbSNP:rs80359198 D → E | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| Y3098HVAR_008794 | 3098 | in BC and ovarian cancer; benign; no effect on homology-directed repair activity; dbSNP:rs41293521 Y → H | Experimental evidence 3 publications Evidence & references
| No verified residues in this structure |
| L3101RVAR_056761 | 3101 | in dbSNP:rs28897758 L → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| I3103MVAR_005109 | 3103 | in melanoma; dbSNP:rs80359204 I → M | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| M3118TVAR_005110 | 3118 | in BC; dbSNP:rs56204128 M → T | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| N3124IVAR_020743 | 3124 | in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs28897759 N → I | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| K3196EVAR_020744 | 3196 | in BC; dbSNP:rs80359228 K → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| V3244IVAR_018917 | 3244 | in dbSNP:rs11571831 V → I | Experimental evidence Evidence & references
| No verified residues in this structure |
| K3257RVAR_008795 | 3257 | in dbSNP:rs55847618 K → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| R3276SVAR_008796 | 3276 | in dbSNP:rs80359245 R → S | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| P3300SVAR_032735 | 3300 | in one patient with esophageal carcinoma; dbSNP:rs770868371 P → S | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T3357RVAR_005111 | 3357 | in BC; dbSNP:rs80358388 T → R | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| T3374IVAR_020745 | 3374 | in dbSNP:rs56309455 T → I | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| I3412VVAR_005112 | 3412 | in dbSNP:rs1801426 I → V | Experimental evidence 7 publications Evidence & references
| No verified residues in this structure |
Laboratory mutagenesis 12
Scroll across the table for evidence and actions.
12 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| R2401A | 2401 | Decreased interaction with DMC1. R → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K2404A | 2404 | Decreased interaction with DMC1. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| FVPP2406AVPA | 2406–2409 | Abolished interaction with DMC1. FVPP → AVPA | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| F2406A | 2406 | Abolished interaction with DMC1. F → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P2408A | 2408 | Abolished interaction with DMC1. P → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| P2409A | 2409 | Abolished interaction with DMC1. P → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| KTK2411ATA | 2411–2413 | Abolished interaction with DMC1. KTK → ATA | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K2411A | 2411 | Does not affect interaction with DMC1. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| K2413A | 2413 | Does not affect interaction with DMC1. K → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| W2725A | 2725 | Disrupts interaction with SEM1. W → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| S3291E | 3291 | Impaired interaction with RAD51. S → E | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| T3387A | 3387 | Loss of phosphorylation by CHEK1 and CHEK2 (in vitro). T → A | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
PTM/Processing
Phosphorylated by ATM upon irradiation-induced DNA damage [13]. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51 [26]. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51-binding [17, 23]
Evidence & references
- ECO:0000269 PubMed:15199141 ↗
- ECO:0000269 PubMed:15800615 ↗
- ECO:0000269 PubMed:17515903 ↗
- ECO:0000269 PubMed:18317453 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15199141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15800615"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515903"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18317453"
}
],
"value": "Phosphorylated by ATM upon irradiation-induced DNA damage (PubMed:15199141). Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51 (PubMed:18317453). Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51-binding (PubMed:15800615, PubMed:17515903)"
}
],
"commentType": "PTM"
}Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation [14]. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation [14]
Evidence & references
- ECO:0000269 PubMed:15314155 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15314155"
}
],
"value": "Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation (PubMed:15314155). In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation (PubMed:15314155)"
}
],
"commentType": "PTM"
}Processed chains & precursor regions 1
Scroll across the table for evidence and actions.
1 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| ChainPRO_0000064984 | 1–3418 | Breast cancer type 2 susceptibility protein | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
Modifications 10
Scroll across the table for evidence and actions.
10 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Modified residue | 70 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 445 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 492 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 755 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 1970 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 2035 | Phosphothreonine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 2095 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 3291 | Phosphoserine; by CDK1 and CDK2 | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Modified residue | 3319 | Phosphoserine | 1 publication Evidence & references
| No verified residues in this structure |
| Modified residue | 3387 | Phosphothreonine; by CHEK1 and CHEK2 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Expression
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen
Evidence & references
- ECO:0000269 PubMed:8589730 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "8589730"
}
],
"value": "Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen"
}
],
"commentType": "TISSUE SPECIFICITY"
}Interaction
Documented interaction partners
UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.
| Partner / product | Species | Experiments | Evidence & actions |
|---|---|---|---|
| BRCA2P51587With P51587 | Homo sapiens | 3 | IntAct evidenceSource product: P51587. Partner: P51587. Reported experiment count: 3. |
| DMC1Q14565With P51587 | Homo sapiens | 12 | IntAct evidenceSource product: P51587. Partner: Q14565. Reported experiment count: 12. |
| FANCD2Q9BXW9With P51587 | Homo sapiens | 16 | IntAct evidenceSource product: P51587. Partner: Q9BXW9. Reported experiment count: 16. |
| FANCD2Q9BXW9-2With P51587 | Homo sapiens | 3 | IntAct evidenceSource product: P51587. Partner: Q9BXW9-2. Reported experiment count: 3. |
| HMG20BQ9P0W2With P51587 | Homo sapiens | 8 | IntAct evidenceSource product: P51587. Partner: Q9P0W2. Reported experiment count: 8. |
| MAP1LC3BQ9GZQ8With P51587 | Homo sapiens | 2 | IntAct evidenceSource product: P51587. Partner: Q9GZQ8. Reported experiment count: 2. |
| PALB2Q86YC2With P51587 | Homo sapiens | 30 | IntAct evidenceSource product: P51587. Partner: Q86YC2. Reported experiment count: 30. |
| PDS5BQ9NTI5With P51587 | Homo sapiens | 26 | IntAct evidenceSource product: P51587. Partner: Q9NTI5. Reported experiment count: 26. |
| POLHQ9Y253With P51587 | Homo sapiens | 6 | IntAct evidenceSource product: P51587. Partner: Q9Y253. Reported experiment count: 6. |
| RAD51Q06609With P51587 | Homo sapiens | 46 | IntAct evidenceSource product: P51587. Partner: Q06609. Reported experiment count: 46. |
| RAD51Q06609-1With P51587 | Homo sapiens | 12 | IntAct evidenceSource product: P51587. Partner: Q06609-1. Reported experiment count: 12. |
| SEM1P60896With P51587 | Homo sapiens | 10 | IntAct evidenceSource product: P51587. Partner: P60896. Reported experiment count: 10. |
| TP53P04637With P51587 | Homo sapiens | 7 | IntAct evidenceSource product: P51587. Partner: P04637. Reported experiment count: 7. |
No partners match this filter.
Complex membership & assembly descriptions
Co-membership does not by itself prove direct binding between every pair.
BRCA1-PALB2-BRCA2 homologous recombination DNA repair complex CPX-845 Complex Portal
Homo sapiens; 9606 ·
Evidence: physical interaction evidence
- PALB2 · Q86YC2 · minValue: 1, maxValue: 1
- BRCA1 · P38398 ·
- BRCA2 · P51587 · minValue: 1, maxValue: 1
Potentiates homologoues recombinational DNA repair (HR) by promoting assembly of RAD51 family of DNA repair proteins onto newly synthesized single-stranded DNA. Act downstream of Fanconi anemia proteins and complexes to repair DNA interstrand crosslinks. The MRN complex (CPX-4442) recruits ATM (Q13315) to the site of double-stranded DNA breaks, which then auto-activates and recruits BRCA1, facilitating a shift from non-homologous end-joining to HR. A newly generated single-strand of DNA is covered by replication protein A (RPA) complex (CPX-1878/CPX-1879). PALB2 is phosphorylated on Ser-59 by ATR (Q13535) and the BRCA1-PALB2-BRCA2 complex forms, promoting RPA removal and RAD51 loading. The resulting RAD51-ssDNA filament invades the intact sister chromatid and the strand is extended through the action of DNA polymerases.
Source & references ↗BRCC E3 ubiquitin ligase complex CPX-955 Complex Portal
Homo sapiens; 9606 ·
Evidence: inferred by curator
- RAD51 · Q06609 ·
- BRCA1 · P38398 ·
- BARD1 · Q99728 ·
- BRCC3 · P46736 ·
- BRCA2 · P51587 ·
- BABAM2 · Q9NXR7 ·
A Ubc5-dependent E3 ubiquitin ligase complex involved in DNA repair, potentially by regulating factors involved in the process. It has a defined substrate specificity, with a strong preference for the nucleosome core histones H2A, H2B, H3 and H4. It co-localizes with, and efficiently ubiquitylates, the histone variant H2AX at sites of DNA damage.
Source & references ↗UniProt subunit description
Monomer and dimer [30]. Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair [11, 47, 17, 18, 22, 23, 26, 27, 32, 29, 31, 40, 46]. Interacts with DMC1; regulates DMC1 recruitment and function at sites of meiotic double-strand breaks (DSBs) [32, 42, 50, 49].
Interacts with WDR16, USP11, DMC1, ROCK2 and NPM1 [14, 19, 33]. Interacts with SEM1; the interaction masks a nuclear export signal in BRCA2 [9, 21, 94, 36]. Interacts with both non-ubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG [12, 13, 25].
Part of a BRCA complex containing BRCA1, BRCA2 and PALB2 [28]. Component of the homologous recombination repair (HR) complex composed of ERCC5/XPG, BRCA2, PALB2, DSS1 and RAD51 [41]. Within the complex, interacts with ERCC5/XPG and PALB2 [41].
Interacts directly with PALB2 which may serve as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51 and XRCC3 [20, 28, 48, 37, 41, 43]. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein [28]. Interacts with POLH; the interaction is direct [38].
Interacts with the TREX-2 complex subunits PCID2 and SEM1 [94, 39]. Interacts with HSF2BP and BRME1; the interaction with HSF2BP is direct and allows the formation of a ternary complex [44]. The complex BRME1:HSF2BP:BRCA2 interacts with SPATA22, MEIOB and RAD51 (By similarity)
Evidence & references
- ECO:0000250 UniProtKB:P97929
- ECO:0000269 PubMed:10373512 ↗
- ECO:0000269 PubMed:11239456 ↗
- ECO:0000269 PubMed:12442171 ↗
- ECO:0000269 PubMed:15115758 ↗
- ECO:0000269 PubMed:15199141 ↗
- ECO:0000269 PubMed:15314155 ↗
- ECO:0000269 PubMed:15800615 ↗
- ECO:0000269 PubMed:15937124 ↗
- ECO:0000269 PubMed:15967112 ↗
- ECO:0000269 PubMed:16205630 ↗
- ECO:0000269 PubMed:16793542 ↗
- ECO:0000269 PubMed:17515903 ↗
- ECO:0000269 PubMed:17515904 ↗
- ECO:0000269 PubMed:18212739 ↗
- ECO:0000269 PubMed:18317453 ↗
- ECO:0000269 PubMed:19303847 ↗
- ECO:0000269 PubMed:19369211 ↗
- ECO:0000269 PubMed:19609323 ↗
- ECO:0000269 PubMed:20729832 ↗
- ECO:0000269 PubMed:20729858 ↗
- ECO:0000269 PubMed:20729859 ↗
- ECO:0000269 PubMed:21076401 ↗
- ECO:0000269 PubMed:21084279 ↗
- ECO:0000269 PubMed:21719596 ↗
- ECO:0000269 PubMed:24013206 ↗
- ECO:0000269 PubMed:24141787 ↗
- ECO:0000269 PubMed:24485656 ↗
- ECO:0000269 PubMed:24896180 ↗
- ECO:0000269 PubMed:26833090 ↗
- ECO:0000269 PubMed:27941124 ↗
- ECO:0000269 PubMed:28319063 ↗
- ECO:0000269 PubMed:31242413 ↗
- ECO:0000269 PubMed:37499663 ↗
- ECO:0000269 PubMed:38828772 ↗
- ECO:0000269 PubMed:39333100 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000250",
"source": "UniProtKB",
"id": "P97929"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "10373512"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "11239456"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "12442171"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15115758"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15199141"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15314155"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15800615"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15937124"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15967112"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16205630"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "16793542"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515903"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515904"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18212739"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "18317453"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19303847"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19369211"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19609323"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729832"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729858"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "20729859"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21076401"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21084279"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "21719596"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24013206"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24141787"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24485656"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "24896180"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "26833090"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "27941124"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "28319063"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "31242413"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "37499663"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "38828772"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "39333100"
}
],
"value": "Monomer and dimer (PubMed:20729858). Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair (PubMed:11239456, PubMed:12442171, PubMed:15800615, PubMed:15937124, PubMed:17515904, PubMed:17515903, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729859, PubMed:21076401, PubMed:27941124, PubMed:37499663). Interacts with DMC1; regulates DMC1 recruitment and function at sites of meiotic double-strand breaks (DSBs) (PubMed:20729832, PubMed:26976601, PubMed:38828772, PubMed:39333100). Interacts with WDR16, USP11, DMC1, ROCK2 and NPM1 (PubMed:15314155, PubMed:15967112, PubMed:21084279). Interacts with SEM1; the interaction masks a nuclear export signal in BRCA2 (PubMed:10373512, PubMed:16205630, PubMed:21719596, PubMed:24013206). Interacts with both non-ubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG (PubMed:15115758, PubMed:15199141, PubMed:18212739). Part of a BRCA complex containing BRCA1, BRCA2 and PALB2 (PubMed:19369211). Component of the homologous recombination repair (HR) complex composed of ERCC5/XPG, BRCA2, PALB2, DSS1 and RAD51 (PubMed:26833090). Within the complex, interacts with ERCC5/XPG and PALB2 (PubMed:26833090). Interacts directly with PALB2 which may serve as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51 and XRCC3 (PubMed:16793542, PubMed:19369211, PubMed:19609323, PubMed:24141787, PubMed:26833090, PubMed:28319063). Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein (PubMed:19369211). Interacts with POLH; the interaction is direct (PubMed:24485656). Interacts with the TREX-2 complex subunits PCID2 and SEM1 (PubMed:21719596, PubMed:24896180). Interacts with HSF2BP and BRME1; the interaction with HSF2BP is direct and allows the formation of a ternary complex (PubMed:31242413). The complex BRME1:HSF2BP:BRCA2 interacts with SPATA22, MEIOB and RAD51 (By similarity)"
}
],
"commentType": "SUBUNIT"
}Other association resources
Resource links only; their association networks and counts are not added to the partner table.
Structure
8C3N · Stapled peptide SP30 in complex with humanised RadA mutant HumRadA22
X-RAY DIFFRACTION · 1.21 Å
Recorded components
| Component | Species | Chains | Protein identities |
|---|---|---|---|
| DNA repair and recombination protein RadAprotein · Entity 1 | Pyrococcus furiosus | A | O74036 |
| Breast cancer type 2 susceptibility proteinprotein · Entity 2 | Homo sapiens | B | P51587 |
| ADENOSINE-5'-DIPHOSPHATEligand · Entity 3 | C | No verified protein mapping | |
| MAGNESIUM IONligand · Entity 4 | D | No verified protein mapping | |
| 4,6-diethylpyrimidin-2-amineligand · Entity 5 | E | No verified protein mapping |
Biological assemblies
Assembly 1 · author_and_software_defined_assembly
Recorded chains: A, B, C, D, E
Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.
Publication
A recombinant approach for stapled peptide discovery yields inhibitors of the RAD51 recombinase.
21/11/2023 · Read publication ↗
Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.
PDB source record ↗Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.
Available structures 14
Scroll across the table for evidence and actions.
14 recorded rows
| Record | Evidence type | Method | Resolution | Open |
|---|---|---|---|---|
| 8C3N | experimental | X-ray | 1.21 A | Open in Atlas ↗ |
| 8BR9 | experimental | X-ray | 1.63 A | Open in Atlas ↗ |
| 1N0W | experimental | X-ray | 1.70 A | Open in Atlas ↗ |
| 6HQU | experimental | X-ray | 1.97 A | Open in Atlas ↗ |
| 3EU7 | experimental | X-ray | 2.20 A | Open in Atlas ↗ |
| 7LDG | experimental | X-ray | 2.56 A | Open in Atlas ↗ |
| 7BDX | experimental | X-ray | 2.60 A | Open in Atlas ↗ |
| 8PBC | experimental | EM | 2.61 A | Open in Atlas ↗ |
| 8UVW | experimental | X-ray | 2.73 A | Open in Atlas ↗ |
| 8PBD | experimental | EM | 2.83 A | Open in Atlas ↗ |
| 8C3J | experimental | X-ray | 3.02 A | Open in Atlas ↗ |
| 6GY2 | experimental | X-ray | 3.11 A | Open in Atlas ↗ |
| 8QQE | experimental | X-ray | 3.46 A | Open in Atlas ↗ |
| 8R2G | experimental | X-ray | 3.45 A | Open in Atlas ↗ |
Family & Domains
Interacts with DMC1 and RAD51 through its eight BRCA2 repeats and its C-terminal TR2 region [18, 23, 22, 27]. The BRCA2 repeats promote RAD51 nucleation on single-stranded DNA (ssDNA) [27]. The TR2 region stabilizes RAD51 oligomers already assembled on ssDNA [23, 22]
Evidence & references
- ECO:0000269 PubMed:15937124 ↗
- ECO:0000269 PubMed:17515903 ↗
- ECO:0000269 PubMed:17515904 ↗
- ECO:0000269 PubMed:19303847 ↗
Complete source annotation
{
"texts": [
{
"evidences": [
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "15937124"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515903"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "17515904"
},
{
"evidenceCode": "ECO:0000269",
"source": "PubMed",
"id": "19303847"
}
],
"value": "Interacts with DMC1 and RAD51 through its eight BRCA2 repeats and its C-terminal TR2 region (PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:19303847). The BRCA2 repeats promote RAD51 nucleation on single-stranded DNA (ssDNA) (PubMed:19303847). The TR2 region stabilizes RAD51 oligomers already assembled on ssDNA (PubMed:17515903, PubMed:17515904)"
}
],
"commentType": "DOMAIN"
}Domain architecture
Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.
Atlas domains, motifs & repeats 15
Scroll across the table for evidence and actions.
15 recorded rows
| Annotation | Position | Source & interpretation | Inspect |
|---|---|---|---|
| BRCA2 repeatIPR002093 | 1002–1036 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1212–1246 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1421–1455 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1517–1551 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1664–1698 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1837–1871 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 1971–2005 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| BRCA2 repeatIPR002093 | 2051–2085 | INTERPROrepeat The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. Full source descriptionThe breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed. | No verified residues in this structure |
| Breast cancer type 2 susceptibility protein, helical domainIPR015252 | 2482–2667 | INTERPROdomain This entry represents a domain found in BRCA2 proteins. This domain adopts a helical structure, consisting of a four-helix cluster core (α1, α8, α9, α10) and two successive β-hairpins (β1 to β4). Full source descriptionThis entry represents a domain found in BRCA2 proteins. This domain adopts a helical structure, consisting of a four-helix cluster core (α1, α8, α9, α10) and two successive β-hairpins (β1 to β4). An approximately 50-amino acid segment that contains four short helices (α2 to α4), meanders around the surface of the core structure. In BRCA2, the α9 and α10 helices pack with BRCA-2_OB1 ([interpro:IPR015187]) through van der Waals contacts involving hydrophobic and aromatic residues, and also through side-chain and backbone hydrogen bonds. This domain binds the 70-amino acid DSS1 (deleted in split-hand/split foot syndrome) protein, which was originally identified as one of three genes that map to a 1.5-Mb locus deleted in an inherited developmental malformation syndrome. | No verified residues in this structure |
| BRCA2, OB1IPR015187 | 2670–2795 | INTERPROdomain No description available for this entry. Source entry ↗ | No verified residues in this structure |
| BRCA2, OB2 domainIPR048262 | 2804–3054 | INTERPROdomain This entry corresponds to the second OB fold domain (OB2) of BRCA2 (breast cancer susceptibility gene 2) protein. BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. Full source descriptionThis entry corresponds to the second OB fold domain (OB2) of BRCA2 (breast cancer susceptibility gene 2) protein. BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein. It also facilitates filament formation. Mutations that map throughout the BRCA2 protein are associated with breast cancer susceptibility. BRCA2 is a large nuclear protein and its most conserved region is the C-terminal. This region binds to ssDNA in vitro, and is composed of five structural domains, three of which are OB folds (OB1, OB2, and OB3). OB2 contains a large insertion, named tower domain that is represented separately by [interpro:IPR015205] but included in this entry. | No verified residues in this structure |
| Tower domainIPR015205 | 2831–2872 | INTERPROdomain This domain adopts a secondary structure consisting of a pair of long, antiparallel α-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a helix-turn-helix motif and is similar to the DNA binding domains of the bacterial site-specific recombinases, and of eukaryotic Myb and homeodomain transcription factors. Full source descriptionThis domain adopts a secondary structure consisting of a pair of long, antiparallel α-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a helix-turn-helix motif and is similar to the DNA binding domains of the bacterial site-specific recombinases, and of eukaryotic Myb and homeodomain transcription factors. The Tower domain has an important role in the tumour suppressor function of BRCA2, and is essential for appropriate binding of BRCA2 to DNA. | No verified residues in this structure |
| BRCA2, OB2PF21318 | 2969–3035 | PFAMdomain BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. t stimulates the displacement of Replication protein A (RPA), and also facilitates filament formation. Full source descriptionBRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. t stimulates the displacement of Replication protein A (RPA), and also facilitates filament formation. This entry represents the second OB fold (OB2) from the C-terminal ssDNA binding domain (DBD) which has three OB folds. OB2 and OB3 are arranged in tandem and their mode of binding can be considered qualitatively similar to two OB folds of RPA1, DBD-A and DBD-B. | No verified residues in this structure |
| BRCA2, OB3IPR015188 | 3052–3185 | INTERPROdomain BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein. Full source descriptionBRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein. Mutations that map throughout the BRCA2 protein are associated with breast cancer susceptibility. BRCA2 is a large nuclear protein and its most conserved region is the C-terminal BRCA2DBD. BRCA2DBD binds ssDNA in vitro, and is composed of five structural domains, three of which are OB folds (OB1, OB2, and OB3). BRCA2DBD OB2 and OB3 are arranged in tandem, and their mode of binding can be considered qualitatively similar to two OB folds of RPA1, DBD-A and DBD-B (the major DBDs of RPA). This entry represents OB3, which consists of a highly curved five-stranded β-sheet that closes on itself to form a β-barrel. OB3 has a pronounced groove formed by one face of the curved sheet and is demarcated by two loops, one between β1 and β2 and another between β4 and β5, which allows for strong ssDNA binding. | No verified residues in this structure |
| BRCA2, TR2 domainIPR055077 | 3260–3334 | INTERPROdomain This domain is found near the C terminus of BRCA2 and similar proteins from vertebrates. It is likely that the TR2 domain is largely disordered and does not fold into a globular structure. Full source descriptionThis domain is found near the C terminus of BRCA2 and similar proteins from vertebrates. It is likely that the TR2 domain is largely disordered and does not fold into a globular structure. It contains a highly conserved proline-rich region which is preceded by a conserved stretch of positively charged residues. This domain is known to interact with meiosis-specific recombinase DMC1 and RAD51. | No verified residues in this structure |
UniProt domains, repeats & motifs 9
Scroll across the table for evidence and actions.
9 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Repeat | 1002–1036 | BRCA2 1 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1212–1246 | BRCA2 2 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1421–1455 | BRCA2 3 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1517–1551 | BRCA2 4 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1664–1698 | BRCA2 5 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1837–1871 | BRCA2 6 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 1971–2005 | BRCA2 7 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Repeat | 2051–2085 | BRCA2 8 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Motif | 2682–2698 | Nuclear export signal; masked by interaction with SEM1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
Functional sites 0
No annotation is recorded in this UniProt entry.
Sequence regions 14
Scroll across the table for evidence and actions.
14 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Region | 1–40 | Interaction with PALB2 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Region | 37–68 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 358–381 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 639–1000 | Interaction with NPM1 | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Region | 1003–2082 | Interaction with RAD51 | By similarity Evidence & references
| No verified residues in this structure |
| Region | 1338–1781 | Interaction with POLH | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Region | 1410–1595 | Required for stimulation of POLH DNA polymerization activity | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Region | 2270–2337 | Interaction with HSF2BP | Experimental evidence 1 publication Evidence & references
| No verified residues in this structure |
| Region | 2350–2545 | Interaction with FANCD2 | Evidence & referencesNo separate evidence record is supplied for this statement. | No verified residues in this structure |
| Region | 2430–2450 | Disordered | Evidence & references
| No verified residues in this structure |
| Region | 2481–2832 | Interaction with SEM1 | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Region | 3265–3330 | TR2 region | Experimental evidence 2 publications Evidence & references
| No verified residues in this structure |
| Region | 3393–3418 | Disordered | Evidence & references
| No verified residues in this structure |
| Compositional bias | 2430–2450 | Basic and acidic residues | Evidence & references
| No verified residues in this structure |
Sequence & Isoforms
Sequence & isoforms
UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.
The mass describes this unmodified source sequence, not every mature or modified product.
MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYISource isoform notes & selection
Isoform sequence differences 0
No annotation is recorded in this UniProt entry.
Sequence conflicts & cautions 5
Scroll across the table for evidence and actions.
5 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Sequence conflict | 758 | in Ref. 1; CAA64484 S → N | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 1761–1762 | in Ref. 1; CAA64484 GY → RI | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 1767 | in Ref. 1; CAA64484 K → N | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 2536 | in Ref. 4; CAA98995 S → P | Curator inference Evidence & references
| No verified residues in this structure |
| Sequence conflict | 3216 | in Ref. 4; CAA97728 L → LVS | Curator inference Evidence & references
| No verified residues in this structure |
Recorded secondary structure 14
Scroll across the table for evidence and actions.
14 recorded rows
| Feature | Position | Description | Evidence | Inspect |
|---|---|---|---|---|
| Helix | 31–35 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 203–206 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1219–1221 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 1228–1230 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1231–1242 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 1257–1259 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 1536–1541 | Helix | Evidence & references
| No verified residues in this structure |
| Turn | 1542–1546 | Turn | Evidence & references
| No verified residues in this structure |
| Beta strand | 2058–2060 | Beta strand | Evidence & references
| No verified residues in this structure |
| Beta strand | 2300–2302 | Beta strand | Evidence & references
| No verified residues in this structure |
| Helix | 2311–2314 | Helix | Evidence & references
| No verified residues in this structure |
| Beta strand | 2315–2317 | Beta strand | Evidence & references
| No verified residues in this structure |
| Turn | 3292–3294 | Turn | Evidence & references
| No verified residues in this structure |
| Helix | 3297–3301 | Helix | Evidence & references
| No verified residues in this structure |
Homologs
OMA orthologs
Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.
Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.
Sources & References
Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.
Source dates & provenance
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:42:04.443696+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:42:04.252664+00:00
- UniProt / The UniProt Consortium ↗ · 2026-11-09T11:42:04.443696+00:00
- InterPro / EMBL-EBI and the member sources identified in the annotations ↗ · 2026-11-09T11:42:04.252664+00:00
- UniProt overview ↗ · 2026-11-10T20:42:48.413020+00:00
- omabrowser.org ↗ · 2026-11-10T21:12:07.702200+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:08.006311+00:00
- omabrowser.org ↗ · 2026-11-10T21:12:08.067575+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:08.228178+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:08.278288+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:08.324844+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:09.283859+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:10.250547+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:10.280657+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:10.607902+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:11.175399+00:00
- rest.uniprot.org ↗ · 2026-11-10T21:12:12.226568+00:00
- www.ebi.ac.uk ↗ · 2026-11-10T21:12:13.569746+00:00
Recorded 2026-11-10. Source dates and identifiers are retained below.
Publications in this UniProt entry
1995 · Nature
PubMed 8524414 ↗Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ALA-2466
Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G., Barfoot R., Hamoudi R., Patel S., Rice C., Biggs P., Hashim Y., Smith A., Connor F., Arason A., Gudmundsson J., Ficenec D., Kelsell D., Ford D., Tonin P., Bishop D.T., Spurr N.K., Ponder B.A.J., Eeles R., Peto J., Devilee P., Cornelisse C., Lynch H., Narod S., Lenoir G., Egilsson V., Barkadottir R.B., Easton D.F., Bentley D.R., Futreal P.A., Ashworth A., Stratton M.R.
1996 · Nat. Genet.
PubMed 8589730 ↗Scope & authors
NUCLEOTIDE SEQUENCE [MRNA]; TISSUE SPECIFICITY; VARIANTS HIS-372 AND PHE-599; VARIANT ALA-2466
Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R., Leblanc J.-F., Mitchell J.T., McArthur-Morrison J., Nguyen K., Peng Y., Samson C., Schroeder M., Snyder S.C., Steele L., Stringfellow M., Stroup C., Swedlund B., Swensen J., Teng D., Thomas A., Tran T., Tran T., Tranchant M., Weaver-Feldhaus J., Wong A.K.C., Shizuya H., Eyfjord J.E., Cannon-Albright L., Labrie F., Skolnick M.H., Weber B., Kamb A., Goldar D.E.
OCT-2003 ·
Scope & authors
NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS HIS-289; GLN-322; HIS-372; VAL-784; SER-929; PHE-976; ILE-987; ASP-991; ASN-1561; LYS-1880; MET-1915; PHE-2138; ARG-2162; ARG-2440; ALA-2466; THR-2490; PRO-2835; ALA-2856; PHE-2944; THR-2951; ILE-3244 AND VAL-3412
2004 · Nature
PubMed 15057823 ↗Scope & authors
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT ALA-2466
Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L., Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.
All source publications (98)
1995 · Lancet
PubMed 7658781 ↗Scope & authors
INVOLVEMENT IN BROVCA2
Thorlacius S., Tryggvadottir L., Olafsdottir G.H., Jonasson J.G., Ogmundsdottir H.M., Tulinius H., Eyfjord J.E.
1997 · Am. J. Hum. Genet.
PubMed 9150155 ↗Scope & authors
INVOLVEMENT IN BROVCA2
Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J.G., Tryggvadottir L., Tulinius H., Eyfjoerd J.E.
1997 · Nat. Genet.
PubMed 9140390 ↗Scope & authors
INVOLVEMENT IN PNCA2
Ozcelik H., Schmocker B., Di Nicola N., Shi X.H., Langer B., Moore M., Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S., Redston M.
1999 · Lancet
PubMed 10584720 ↗Scope & authors
INVOLVEMENT IN BROVCA2
Jernstroem H., Lerman C., Ghadirian P., Lynch H.T., Weber B., Garber J., Daly M., Olopade O.I., Foulkes W.D., Warner E., Brunet J.S., Narod S.A.
1999 · Mol. Cell. Biol.
PubMed 10373512 ↗Scope & authors
INTERACTION WITH SEM1
Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J., Ashworth A.
2001 · J. Med. Genet.
PubMed 11158174 ↗Scope & authors
INVOLVEMENT IN BROVCA2
van der Luijt R.B., van Zon P.H., Jansen R.P., van der Sijs-Bos C.J., Warlam-Rodenhuis C.C., Ausems M.G.
2001 · Mol. Cell
PubMed 11239456 ↗Scope & authors
FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51
Davies A.A., Masson J.Y., McIlwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., West S.C.
2004 · Hum. Mol. Genet.
PubMed 15115758 ↗Scope & authors
FUNCTION; INTERACTION WITH FANCD2
Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S., Davies A., Masson J.-Y., Moses R., West S.C., de Winter J.P., Ashworth A., Jones N.J., Mathew C.G.
2004 · Mol. Cell. Biol.
PubMed 15199141 ↗Scope & authors
FUNCTION; PHOSPHORYLATION; INTERACTION WITH FANCD2
Wang X.Z., Andreassen P.R., D'Andrea A.D.
2004 · Mol. Cell. Biol.
PubMed 15314155 ↗Scope & authors
UBIQUITINATION; DEUBIQUITINATION; INTERACTION WITH USP11
Schoenfeld A.R., Apgar S., Dolios G., Wang R., Aaronson S.A.
2005 · J. Med. Genet.
PubMed 15689453 ↗Scope & authors
INVOLVEMENT IN GLM3
Reid S., Renwick A., Seal S., Baskcomb L., Barfoot R., Jayatilake H., Pritchard-Jones K., Stratton M.R., Ridolfi-Luethy A., Rahman N.
2005 · J. Biol. Chem.
PubMed 15671039 ↗Scope & authors
FUNCTION
Ohashi A., Zdzienicka M.Z., Chen J., Couch F.J.
2005 · Nature
PubMed 15800615 ↗Scope & authors
PHOSPHORYLATION AT SER-3291 BY CDK2; INTERACTION WITH RAD51; MUTAGENESIS OF SER-3291
Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C.
2005 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 15937124 ↗Scope & authors
FUNCTION; INTERACTION WITH RAD51; DOMAIN
Galkin V.E., Esashi F., Yu X., Yang S., West S.C., Egelman E.H.
2005 · Neoplasia
PubMed 15967112 ↗Scope & authors
INTERACTION WITH WDR16
Silva F.P., Hamamoto R., Nakamura Y., Furukawa Y.
2006 · Mol. Cell
PubMed 16793542 ↗Scope & authors
INTERACTION WITH PALB2; CHARACTERIZATION OF VARIANTS BC ARG-25; CYS-31 AND ARG-31
Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch F.J., Livingston D.M.
2006 · Oncogene
PubMed 16205630 ↗Scope & authors
INTERACTION WITH SEM1
Li J., Zou C., Bai Y., Wazer D.E., Band V., Gao Q.
2007 · Nat. Struct. Mol. Biol.
PubMed 17515904 ↗Scope & authors
FUNCTION; INTERACTION WITH RAD51; DOMAIN
Esashi F., Galkin V.E., Yu X., Egelman E.H., West S.C.
2007 · Nat. Struct. Mol. Biol.
PubMed 17515903 ↗Scope & authors
FUNCTION; INTERACTION WITH RAD51; DOMAIN; PHOSPHORYLATION AT SER-3291
Davies O.R., Pellegrini L.
2007 · Science
PubMed 17525332 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-755; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.
2008 · Oncogene
PubMed 18212739 ↗Scope & authors
INTERACTION WITH FANCD2; FANCG AND XRCC3
Wilson J.B., Yamamoto K., Marriott A.S., Hussain S., Sung P., Hoatlin M.E., Mathew C.G., Takata M., Thompson L.H., Kupfer G.M., Jones N.J.
2008 · Oncogene
PubMed 18317453 ↗Scope & authors
FUNCTION IN RAD51-DEPENDENT DNA REPAIR; PHOSPHORYLATION AT THR-3387 BY CHEK1 AND CHEK2; MUTAGENESIS OF THR-3387; INTERACTION WITH RAD51
Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E., Stambrook P.J.
2009 · Cell
PubMed 19303847 ↗Scope & authors
FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51; DOMAIN
Carreira A., Hilario J., Amitani I., Baskin R.J., Shivji M.K., Venkitaraman A.R., Kowalczykowski S.C.
2009 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 19369211 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY; IDENTIFICATION IN A BRCA COMPLEX WITH BRCA1 AND PALB2
Sy S.M., Huen M.S., Chen J.
2010 · Nat. Struct. Mol. Biol.
PubMed 20729859 ↗Scope & authors
FUNCTION; INTERACTION WITH RAD51
Liu J., Doty T., Gibson B., Heyer W.D.
2010 · Nat. Struct. Mol. Biol.
PubMed 20729858 ↗Scope & authors
FUNCTION; SUBUNIT
Thorslund T., McIlwraith M.J., Compton S.A., Lekomtsev S., Petronczki M., Griffith J.D., West S.C.
2010 · Nat. Struct. Mol. Biol.
PubMed 21076401 ↗Scope & authors
FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51
Badie S., Escandell J.M., Bouwman P., Carlos A.R., Thanasoula M., Gallardo M.M., Suram A., Jaco I., Benitez J., Herbig U., Blasco M.A., Jonkers J., Tarsounas M.
2010 · Nature
PubMed 20729832 ↗Scope & authors
IDENTIFICATION BY MASS SPECTROMETRY; FUNCTION; INTERACTION WITH RAD51 AND DMC1
Jensen R.B., Carreira A., Kowalczykowski S.C.
2011 · Cancer Res.
PubMed 21084279 ↗Scope & authors
FUNCTION; INTERACTION WITH ROCK2 AND NPM1
Wang H.F., Takenaka K., Nakanishi A., Miki Y.
2011 · Exp. Cell Res.
PubMed 21276791 ↗Scope & authors
SUBCELLULAR LOCATION
Cappelli E., Townsend S., Griffin C., Thacker J.
2013 · J. Proteome Res.
PubMed 23186163 ↗Scope & authors
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-445; SER-492; SER-1970; THR-2035; SER-2095 AND SER-3319; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.
2013 · Nat. Struct. Mol. Biol.
PubMed 24013206 ↗Scope & authors
INTERACTION WITH SEM1; CHARACTERIZATION OF VARIANT BC HIS-2723; MUTAGENESIS OF TRP-2725; NUCLEAR EXPORT SIGNAL; SUBCELLULAR LOCATION
Jeyasekharan A.D., Liu Y., Hattori H., Pisupati V., Jonsdottir A.B., Rajendra E., Lee M., Sundaramoorthy E., Schlachter S., Kaminski C.F., Ofir-Rosenfeld Y., Sato K., Savill J., Ayoub N., Venkitaraman A.R.
2014 · Oncogene
PubMed 24141787 ↗Scope & authors
INTERACTION WITH PALB2; IDENTIFICATION IN A PALB2-CONTAINING HR COMPLEX
Park J.Y., Singh T.R., Nassar N., Zhang F., Freund M., Hanenberg H., Meetei A.R., Andreassen P.R.
2014 · Cell Rep.
PubMed 24485656 ↗Scope & authors
FUNCTION; INTERACTION WITH POLH
Buisson R., Niraj J., Pauty J., Maity R., Zhao W., Coulombe Y., Sung P., Masson J.Y.
2014 · Nature
PubMed 24896180 ↗Scope & authors
FUNCTION IN R-LOOP PROCESSING; INTERACTION WITH SEM1 AND PCID2
Bhatia V., Barroso S.I., Garcia-Rubio M.L., Tumini E., Herrera-Moyano E., Aguilera A.
2016 · Genes Dev.
PubMed 27941124 ↗Scope & authors
FUNCTION; INTERACTION WITH RAD51
Luo K., Li L., Li Y., Wu C., Yin Y., Chen Y., Deng M., Nowsheen S., Yuan J., Lou Z.
2016 · Mol. Cell
PubMed 26833090 ↗Scope & authors
IDENTIFICATION IN THE HR COMPLEX; INTERACTION WITH ERCC5 AND PALB2; SUBCELLULAR LOCATION
Trego K.S., Groesser T., Davalos A.R., Parplys A.C., Zhao W., Nelson M.R., Hlaing A., Shih B., Rydberg B., Pluth J.M., Tsai M.S., Hoeijmakers J.H.J., Sung P., Wiese C., Campisi J., Cooper P.K.
2016 · Proc. Natl. Acad. Sci. U.S.A.
PubMed 26976601 ↗Scope & authors
FUNCTION; INTERACTION WITH DMC1
Martinez J.S., von Nicolai C., Kim T., Ehlen A., Mazin A.V., Kowalczykowski S.C., Carreira A.
2017 · Oncogene
PubMed 28319063 ↗Scope & authors
INTERACTION WITH PALB2
Foo T.K., Tischkowitz M., Simhadri S., Boshari T., Zayed N., Burke K.A., Berman S.H., Blecua P., Riaz N., Huo Y., Ding Y.C., Neuhausen S.L., Weigelt B., Reis-Filho J.S., Foulkes W.D., Xia B.
2019 · Cell Rep.
PubMed 31242413 ↗Scope & authors
INTERACTION WITH HSF2BP
Brandsma I., Sato K., van Rossum-Fikkert S.E., van Vliet N., Sleddens E., Reuter M., Odijk H., van den Tempel N., Dekkers D.H.W., Bezstarosti K., Demmers J.A.A., Maas A., Lebbink J., Wyman C., Essers J., van Gent D.C., Baarends W.M., Knipscheer P., Kanaar R., Zelensky A.N.
2023 · Cell Rep.
PubMed 37515771 ↗Scope & authors
FUNCTION
Zhou Z., Yang H., Liang X., Zhou T., Zhang T., Yang Y., Wang J., Wang W.
2023 · Mol. Cell
PubMed 37499663 ↗Scope & authors
FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51
Belan O., Greenhough L., Kuhlen L., Anand R., Kaczmarczyk A., Gruszka D.T., Yardimci H., Zhang X., Rueda D.S., West S.C., Boulton S.J.
2002 · Nature
PubMed 12442171 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH RAD51; FUNCTION; INTERACTION WITH RAD51
Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., Venkitaraman A.R.
2009 · EMBO Rep.
PubMed 19609323 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH PALB2
Oliver A.W., Swift S., Lord C.J., Ashworth A., Pearl L.H.
2024 · Nat. Commun.
PubMed 39333100 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH DMC1; INTERACTION WITH DMC1; MUTAGENESIS OF PHE-2406; PRO-2408 AND PRO-2409
Dunce J.M., Davies O.R.
2024 · Nucleic Acids Res.
PubMed 38828772 ↗Scope & authors
X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH DMC1; INTERACTION WITH DMC1; MUTAGENESIS OF ARG-2401; LYS-2404; 2406-PHE--PRO-2409; 2411-LYS--LYS-2413; LYS-2411 AND LYS-2413
Miron S., Legrand P., Dupaigne P., van Rossum-Fikkert S.E., Ristic D., Majeed A., Kanaar R., Zinn-Justin S., Zelensky A.N.
1996 · Cancer Res.
PubMed 8665505 ↗Scope & authors
VARIANT OVARIAN CANCER HIS-2787; VARIANTS HIS-372; MET-1915 AND ALA-2466
Takahashi H., Chiu H.-C., Bandera C.A., Behbakht K., Liu P.C., Couch F.J., Weber B.L., LiVolsi V.A., Furusato M., Rebane B.A., Cardonick A., Benjamin I., Morgan M.A., King S.A., Mikuta J.J., Rubin S.C., Boyd J.
1996 · Nat. Genet.
PubMed 8673091 ↗Scope & authors
VARIANTS HIS-372; ASP-991; SER-1147; MET-1915 AND CYS-2034
Couch F.J., Farid L.M., Deshano M.L., Tavtigian S.V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., Shattuck-Eidens D., Godwin A.K., Daly M., Radford D.M., Sedlacek S., Rommens J., Simard J., Garber J., Merajver S., Weber B.L.
1996 · Nat. Genet.
PubMed 8640235 ↗Scope & authors
VARIANT GLU-3095
Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G., Patel S., Hamoudi R., Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D., Marks J.R., Ashworth A., Stratton M.R., Futreal P.A.
1996 · Nat. Genet.
PubMed 8640236 ↗Scope & authors
VARIANTS
Teng D.H.-F., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., Davis T., Ha P.C., Kehrer R., Jammulapati S., Chen Q., Offit K., Skolnick M.H., Tavtigian S.V., Jhanwar S., Swedlund B., Wong A.K.C., Kamb A.
1996 · Nat. Genet.
PubMed 8640237 ↗Scope & authors
VARIANT BC ASN-2415
Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y.
1997 · Am. J. Hum. Genet.
PubMed 9150152 ↗Scope & authors
VARIANT BC ASP-2089; VARIANT VAL-3412
Vehmanen P., Friedman L.S., Eerola H., Sarantaus L., Pyrhoenen S., Ponder B.A.J., Muhonen T., Nevanlinna H.
1998 · Hum. Genet.
PubMed 9654203 ↗Scope & authors
VARIANT BC/PANCREAS CANCER TRP-554
Ganguly T., Dhulipala R., Godmilow L., Ganguly A.
1998 · J. Hum. Genet.
PubMed 9609997 ↗Scope & authors
VARIANTS BC LEU-32; ARG-53; LEU-81; ARG-201; ALA-211; SER-222 AND THR-3118
Katagiri T., Kasumi F., Yoshimoto M., Nomizu T., Asaishi K., Abe R., Tsuchiya A., Sugano M., Takai S., Yoneda M., Fukutomi T., Nanba K., Makita M., Okazaki H., Hirata K., Okazaki M., Furutsuma Y., Morishita Y., Iino Y., Karino T., Ayabe H., Hara S., Kajiwara T., Houga S., Shimizu T., Toda M., Yamazaki Y., Uchida T., Kunitomo K., Sonoo H., Kurebayashi J., Shimotsuma K., Nakamura Y., Miki Y.
1999 · Am. J. Hum. Genet.
PubMed 10486320 ↗Scope & authors
VARIANTS OVARIAN CANCER PRO-75; HIS-2502 AND HIS-3098
Gayther S.A., Russell P., Harrington P., Antoniou A.C., Easton D.F., Ponder B.A.J.
1999 · Hum. Genet.
PubMed 10323242 ↗Scope & authors
VARIANTS HIS-289; HIS-372; ASP-991 AND VAL-3412
Li S.S.-L., Tseng H.-M., Yang T.-P., Liu C.-H., Teng S.-J., Huang H.-W., Chen L.-M., Kao H.-W., Chen J.H., Tseng J.-N., Chen A., Hou M.-F., Huang T.-J., Chang H.-T., Mok K.-T., Tsai J.-H.
1999 · Hum. Mol. Genet.
PubMed 9971877 ↗Scope & authors
VARIANTS BC GLU-327 AND ASN-935; VARIANTS
Wagner T.M.U., Hirtenlehner K., Shen P., Moeslinger R., Muhr D., Fleischmann E., Concin H., Doeller W., Haid A., Lang A.H., Mayer P., Petru E., Ropp E., Langbauer G., Kubista E., Scheiner O., Underhill P., Mountain J., Stierer M., Zielinski C., Oefner P.
1999 · Int. J. Cancer
PubMed 10399947 ↗Scope & authors
VARIANT BC ARG-326; VARIANT ILE-2728
Sinilnikova O.M., Egan K.M., Quinn J.L., Boutrand L., Lenoir G.M., Stoppa-Lyonnet D., Desjardins L., Levy C., Goldgar D., Gragoudas E.S.
2000 · Nat. Genet.
PubMed 11062481 ↗Scope & authors
VARIANT HIS-372
Healey C.S., Dunning A.M., Teare M.D., Chase D., Parker L., Burn J., Chang-Claude J., Mannermaa A., Kataja V., Huntsman D.G., Pharoah P.D.P., Luben R.N., Easton D.F., Ponder B.A.J.
2000 · J. Med. Genet.
PubMed 10978364 ↗Scope & authors
VARIANTS BC MET-729; ILE-2515 AND ILE-2728; VARIANTS HIS-289; HIS-372; ASP-991; MET-1915 AND VAL-3412
Plaschke J., Commer T., Jacobi C., Schackert H.K., Chang-Claude J.
2001 · Hum. Mutat.
PubMed 11139248 ↗Scope & authors
VARIANTS BC ASN-1179; ILE-3124 AND GLU-3196; VARIANT TYR-1420
Kwiatkowska E., Teresiak M., Lamperska K.M., Karczewska A., Breborowicz D., Stawicka M., Godlewski D., Krzyzosiak W.J., Mackiewicz A.
2001 · Hum. Mutat.
PubMed 11241844 ↗Scope & authors
VARIANTS BC THR-505; TYR-1730; HIS-2135 AND CYS-2222; VARIANT LYS-1880
Edwards S.M., Kote-Jarai Z., Hamoudi R., Eeles R.A.
2001 · Int. J. Cancer
PubMed 11149425 ↗Scope & authors
VARIANTS HIS-289 AND VAL-784; VARIANT BC GLU-3076
Ikeda N., Miyoshi Y., Yoneda K., Shiba E., Sekihara Y., Kinoshita M., Noguchi S.
2002 · Am. J. Hum. Genet.
PubMed 12145750 ↗Scope & authors
VARIANT BC ARG-2722
Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.
2002 · Am. J. Hum. Genet.
Scope & authors
ERRATUM OF PUBMED:12145750
Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.
2002 · Br. J. Cancer
PubMed 12373604 ↗Scope & authors
VARIANTS BC CYS-2072; CYS-2094 AND ASN-2128
Jakubowska A., Nej K., Huzarski T., Scott R.J., Lubinski J.
2002 · Cancer Res.
PubMed 12097290 ↗Scope & authors
VARIANT THR-192
Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Hruban R.H., Kern S.E.
2002 · Clin. Cancer Res.
PubMed 11948123 ↗Scope & authors
VARIANTS HIS-118; SER-315; ILE-1988; CYS-2842 AND SER-3300
Hu N., Li G., Li W.-J., Wang C., Goldstein A.M., Tang Z.-Z., Roth M.J., Dawsey S.M., Huang J., Wang Q.-H., Ding T., Giffen C., Taylor P.R., Emmert-Buck M.R.
2002 · Genet. Test.
PubMed 12215251 ↗Scope & authors
VARIANTS ALA-598; TYR-1420; CYS-2034; ILE-2728 AND THR-2951
Deffenbaugh A.M., Frank T.S., Hoffman M., Cannon-Albright L., Neuhausen S.L.
2002 · Hum. Mutat.
PubMed 12442273 ↗Scope & authors
VARIANTS ASP-1593 AND SER-2706
Saxena S., Szabo C.I., Chopin S., Barjhoux L., Sinilnikova O., Lenoir G., Goldgar D.E., Bhatanager D.
2002 · Hum. Mutat.
PubMed 12442274 ↗Scope & authors
VARIANT BC ASN-2729; VARIANT VAL-3412
Zhi X., Szabo C., Chopin S., Suter N., Wang Q.-S., Ostrander E.A., Sinilnikova O.M., Lenoir G.M., Goldgar D., Shi Y.-R.
2002 · Hum. Mutat.
PubMed 12442275 ↗Scope & authors
VARIANTS BC CYS-42; ARG-613; LEU-2118; LEU-2293 AND ARG-2793; VARIANT ILE-3374
Ruiz-Flores P., Sinilnikova O.M., Badzioch M., Calderon-Garciduenas A.L., Chopin S., Fabrice O., Gonzalez-Guerrero J.F., Szabo C., Lenoir G., Goldgar D.E., Barrera-Saldana H.A.
2002 · Int. J. Cancer
PubMed 11948477 ↗Scope & authors
VARIANTS BC TYR-1580 AND MET-1915
Kwiatkowska E., Teresiak M., Breborowicz D., Mackiewicz A.
2002 · Science
PubMed 12065746 ↗Scope & authors
INVOLVEMENT IN FANCD1
Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., de Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., D'Andrea A.D.
2003 · Hum. Mutat.
PubMed 12552570 ↗Scope & authors
VARIANTS HIS-289; HIS-372; GLY-462; ASP-991; SER-1279; TYR-1420; ASP-1771 AND ALA-2466
Hadjisavvas A., Charalambous E., Adamou A., Christodoulou C.G., Kyriacou K.
2003 · Hum. Mutat.
PubMed 12938098 ↗Scope & authors
VARIANTS BC ILE-431; LYS-1036; ARG-1106 AND VAL-1524
Meyer P., Voigtlaender T., Bartram C.R., Klaes R.
2003 · J. Hum. Genet.
PubMed 12624724 ↗Scope & authors
VARIANTS PRO-582; PHE-1522 AND VAL-2044
Sakayori M., Kawahara M., Shiraishi K., Nomizu T., Shimada A., Kudo T., Abe R., Ohuchi N., Takenoshita S., Kanamaru R., Ishioka C.
2003 · J. Natl. Cancer Inst.
PubMed 12569143 ↗Scope & authors
VARIANT CYS-2034; VARIANT BC GLU-3076
Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Gruetzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K.
2004 · Blood
PubMed 14670928 ↗Scope & authors
VARIANT FANCD1 PRO-2510
Hirsch B., Shimamura A., Moreau L., Baldinger S., Hag-alshiekh M., Bostrom B., Sencer S., D'Andrea A.D.
2004 · Br. J. Cancer
PubMed 15026808 ↗Scope & authors
VARIANTS BC SER-60; ARG-405; HIS-448; GLY-462; GLY-2275; ARG-2353; LYS-2488; HIS-2723; ASN-2950; ILE-3013 AND HIS-3098; VARIANTS ASP-991; ALA-2856 AND VAL-3412
Claes K., Poppe B., Coene I., De Paepe A., Messiaen L.
2004 · Cancer Genet. Cytogenet.
PubMed 15172753 ↗Scope & authors
VARIANTS BC ILE-64; GLY-462; ASN-1690; ASP-1771; MET-1887; MET-1915 AND GLU-2456; VARIANTS HIS-289; HIS-372; ASP-991; SER-1279; TYR-1420; CYS-2108 AND ALA-2466
Hadjisavvas A., Charalambous E., Adamou A., Neuhausen S.L., Christodoulou C.G., Kyriacou K.
2004 · Eur. J. Cancer
PubMed 14746861 ↗Scope & authors
VARIANT OVARIAN CANCER CYS-42; VARIANTS SER-3063 AND VAL-3412
Malander S., Ridderheim M., Masbaeck A., Loman N., Kristoffersson U., Olsson H., Nilbert M., Borg A.
2004 · Hum. Mutat.
PubMed 14722926 ↗Scope & authors
VARIANTS BC ILE-1679; ALA-1804; LYS-1901 AND LEU-2096
Valarmathi M.T., Sawhney M., Deo S.S.V., Shukla N.K., Das S.N.
2004 · Hum. Mutat.
PubMed 15300854 ↗Scope & authors
VARIANT ALA-225; CHARACTERIZATION OF VARIANT ALA-225
Sharp A., Pichert G., Lucassen A., Eccles D.
2004 · Hum. Mutat.
PubMed 15365993 ↗Scope & authors
VARIANTS BC THR-1445; VAL-1929 AND ALA-2031; VARIANTS HIS-289; HIS-372; VAL-784; ASP-991 AND VAL-3412
Seo J.H., Cho D.-Y., Ahn S.-H., Yoon K.-S., Kang C.-S., Cho H.M., Lee H.S., Choe J.J., Choi C.W., Kim B.S., Shin S.W., Kim Y.H., Kim J.S., Son G.-S., Lee J.-B., Koo B.H.
2005 · J. Med. Genet.
PubMed 15635067 ↗Scope & authors
VARIANTS LEU-1172; TYR-1420; PHE-2944; ASN-2950 AND ILE-3013
Kim S.-W., Lee C.S., Fey J.V., Borgen P.I., Boyd J.
2007 · Am. J. Hum. Genet.
PubMed 17924331 ↗Scope & authors
VARIANTS BC CYS-2502; PHE-2627; PRO-2653; LYS-2659; VAL-2663; ARG-2722; GLY-2723; ASP-2748 AND GLU-3095; VARIANTS FANCD1 HIS-2336 AND CYS-2626
Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J., Allen-Brady K., Tavtigian S.V., Monteiro A.N.A., Iversen E.S., Couch F.J., Goldgar D.E.
2007 · J. Med. Genet.
PubMed 16825431 ↗Scope & authors
VARIANTS FANCD1 HIS-2336 AND CYS-2626
Alter B.P., Rosenberg P.S., Brody L.C.
2010 · Hum. Mutat.
PubMed 20513136 ↗Scope & authors
CHARACTERIZATION OF VARIANTS VAL-2663; GLY-2723 AND TRP-3052
Walker L.C., Whiley P.J., Couch F.J., Farrugia D.J., Healey S., Eccles D.M., Lin F., Butler S.A., Goff S.A., Thompson B.A., Lakhani S.R., Da Silva L.M., Tavtigian S.V., Goldgar D.E., Brown M.A., Spurdle A.B.
2011 · Blood
PubMed 21719596 ↗Scope & authors
CHARACTERIZATION OF VARIANTS FANCD1 HIS-2336; PRO-2510 AND CYS-2626; CHARACTERIZATION OF VARIANTS THR-2490 AND ASN-2729; FUNCTION; INTERACTION WITH SEM1
Biswas K., Das R., Alter B.P., Kuznetsov S.G., Stauffer S., North S.L., Burkett S., Brody L.C., Meyer S., Byrd R.A., Sharan S.K.
2013 · Cancer Res.
PubMed 23108138 ↗Scope & authors
CHARACTERIZATION OF VARIANTS BC PHE-2627; PRO-2653; ARG-2722; GLY-2723; HIS-2723; ASN-2729; HIS-2787; PRO-2792; ARG-2793; ALA-2856; THR-2951; ILE-3013; TRP-3052; GLU-3076; GLU-3095; HIS-3098 AND ILE-3124; CHARACTERIZATION OF VARIANTS ARG-2440; ALA-2466; CYS-2842 AND SER-3063; CHARACTERIZATION OF VARIANT FANCD1 PRO-2510 AND CYS-2626
Guidugli L., Pankratz V.S., Singh N., Thompson J., Erding C.A., Engel C., Schmutzler R., Domchek S., Nathanson K., Radice P., Singer C., Tonin P.N., Lindor N.M., Goldgar D.E., Couch F.J.
2016 · J. Med. Genet.
PubMed 26566883 ↗Scope & authors
VARIANTS LEU-606 AND TYR-1420
Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G., Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.
2017 · PLoS ONE
PubMed 29161300 ↗Scope & authors
VARIANT BC ALA-728
Alemar B., Gregorio C., Herzog J., Matzenbacher Bittar C., Brinckmann Oliveira Netto C., Artigalas O., Schwartz I.V.D., Coffa J., Alves Camey S., Weitzel J., Ashton-Prolla P.
2018 · Lancet Oncol.
PubMed 29753700 ↗Scope & authors
INVOLVEMENT IN MDB
Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.
Fanconi Anemia Mutation Database ↗
Atlas of Genetics and Cytogenetics in Oncology and Haematology ↗
Annotation coverage audit
Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.
242 source comments and features accounted for.
View annotation inventory
| Source record | Type | Section |
|---|---|---|
| FUNCTION:0 | FUNCTION | function |
| SUBUNIT:0 | SUBUNIT | interactions |
| INTERACTION:0 | INTERACTION | interactions |
| SUBCELLULAR LOCATION:0 | SUBCELLULAR LOCATION | location |
| TISSUE SPECIFICITY:0 | TISSUE SPECIFICITY | expression |
| DOMAIN:0 | DOMAIN | domains |
| PTM:0 | PTM | processing |
| PTM:1 | PTM | processing |
| DISEASE:0 | DISEASE | disease |
| DISEASE:1 | DISEASE | disease |
| DISEASE:2 | DISEASE | disease |
| DISEASE:3 | DISEASE | disease |
| DISEASE:4 | DISEASE | disease |
| DISEASE:5 | DISEASE | disease |
| WEB RESOURCE:0 | WEB RESOURCE | sources |
| WEB RESOURCE:1 | WEB RESOURCE | sources |
| WEB RESOURCE:2 | WEB RESOURCE | sources |
| feature-0 | Chain | processing |
| feature-1 | Repeat | domains |
| feature-2 | Repeat | domains |
| feature-3 | Repeat | domains |
| feature-4 | Repeat | domains |
| feature-5 | Repeat | domains |
| feature-6 | Repeat | domains |
| feature-7 | Repeat | domains |
| feature-8 | Repeat | domains |
| feature-9 | Region | domains |
| feature-10 | Region | domains |
| feature-11 | Region | domains |
| feature-12 | Region | domains |
| feature-13 | Region | domains |
| feature-14 | Region | domains |
| feature-15 | Region | domains |
| feature-16 | Region | domains |
| feature-17 | Region | domains |
| feature-18 | Region | domains |
| feature-19 | Region | domains |
| feature-20 | Region | domains |
| feature-21 | Region | domains |
| feature-22 | Motif | domains |
| feature-23 | Compositional bias | domains |
| feature-24 | Modified residue | processing |
| feature-25 | Modified residue | processing |
| feature-26 | Modified residue | processing |
| feature-27 | Modified residue | processing |
| feature-28 | Modified residue | processing |
| feature-29 | Modified residue | processing |
| feature-30 | Modified residue | processing |
| feature-31 | Modified residue | processing |
| feature-32 | Modified residue | processing |
| feature-33 | Modified residue | processing |
| feature-34 | Natural variant | disease |
| feature-35 | Natural variant | disease |
| feature-36 | Natural variant | disease |
| feature-37 | Natural variant | disease |
| feature-38 | Natural variant | disease |
| feature-39 | Natural variant | disease |
| feature-40 | Natural variant | disease |
| feature-41 | Natural variant | disease |
| feature-42 | Natural variant | disease |
| feature-43 | Natural variant | disease |
| feature-44 | Natural variant | disease |
| feature-45 | Natural variant | disease |
| feature-46 | Natural variant | disease |
| feature-47 | Natural variant | disease |
| feature-48 | Natural variant | disease |
| feature-49 | Natural variant | disease |
| feature-50 | Natural variant | disease |
| feature-51 | Natural variant | disease |
| feature-52 | Natural variant | disease |
| feature-53 | Natural variant | disease |
| feature-54 | Natural variant | disease |
| feature-55 | Natural variant | disease |
| feature-56 | Natural variant | disease |
| feature-57 | Natural variant | disease |
| feature-58 | Natural variant | disease |
| feature-59 | Natural variant | disease |
| feature-60 | Natural variant | disease |
| feature-61 | Natural variant | disease |
| feature-62 | Natural variant | disease |
| feature-63 | Natural variant | disease |
| feature-64 | Natural variant | disease |
| feature-65 | Natural variant | disease |
| feature-66 | Natural variant | disease |
| feature-67 | Natural variant | disease |
| feature-68 | Natural variant | disease |
| feature-69 | Natural variant | disease |
| feature-70 | Natural variant | disease |
| feature-71 | Natural variant | disease |
| feature-72 | Natural variant | disease |
| feature-73 | Natural variant | disease |
| feature-74 | Natural variant | disease |
| feature-75 | Natural variant | disease |
| feature-76 | Natural variant | disease |
| feature-77 | Natural variant | disease |
| feature-78 | Natural variant | disease |
| feature-79 | Natural variant | disease |
| feature-80 | Natural variant | disease |
| feature-81 | Natural variant | disease |
| feature-82 | Natural variant | disease |
| feature-83 | Natural variant | disease |
| feature-84 | Natural variant | disease |
| feature-85 | Natural variant | disease |
| feature-86 | Natural variant | disease |
| feature-87 | Natural variant | disease |
| feature-88 | Natural variant | disease |
| feature-89 | Natural variant | disease |
| feature-90 | Natural variant | disease |
| feature-91 | Natural variant | disease |
| feature-92 | Natural variant | disease |
| feature-93 | Natural variant | disease |
| feature-94 | Natural variant | disease |
| feature-95 | Natural variant | disease |
| feature-96 | Natural variant | disease |
| feature-97 | Natural variant | disease |
| feature-98 | Natural variant | disease |
| feature-99 | Natural variant | disease |
| feature-100 | Natural variant | disease |
| feature-101 | Natural variant | disease |
| feature-102 | Natural variant | disease |
| feature-103 | Natural variant | disease |
| feature-104 | Natural variant | disease |
| feature-105 | Natural variant | disease |
| feature-106 | Natural variant | disease |
| feature-107 | Natural variant | disease |
| feature-108 | Natural variant | disease |
| feature-109 | Natural variant | disease |
| feature-110 | Natural variant | disease |
| feature-111 | Natural variant | disease |
| feature-112 | Natural variant | disease |
| feature-113 | Natural variant | disease |
| feature-114 | Natural variant | disease |
| feature-115 | Natural variant | disease |
| feature-116 | Natural variant | disease |
| feature-117 | Natural variant | disease |
| feature-118 | Natural variant | disease |
| feature-119 | Natural variant | disease |
| feature-120 | Natural variant | disease |
| feature-121 | Natural variant | disease |
| feature-122 | Natural variant | disease |
| feature-123 | Natural variant | disease |
| feature-124 | Natural variant | disease |
| feature-125 | Natural variant | disease |
| feature-126 | Natural variant | disease |
| feature-127 | Natural variant | disease |
| feature-128 | Natural variant | disease |
| feature-129 | Natural variant | disease |
| feature-130 | Natural variant | disease |
| feature-131 | Natural variant | disease |
| feature-132 | Natural variant | disease |
| feature-133 | Natural variant | disease |
| feature-134 | Natural variant | disease |
| feature-135 | Natural variant | disease |
| feature-136 | Natural variant | disease |
| feature-137 | Natural variant | disease |
| feature-138 | Natural variant | disease |
| feature-139 | Natural variant | disease |
| feature-140 | Natural variant | disease |
| feature-141 | Natural variant | disease |
| feature-142 | Natural variant | disease |
| feature-143 | Natural variant | disease |
| feature-144 | Natural variant | disease |
| feature-145 | Natural variant | disease |
| feature-146 | Natural variant | disease |
| feature-147 | Natural variant | disease |
| feature-148 | Natural variant | disease |
| feature-149 | Natural variant | disease |
| feature-150 | Natural variant | disease |
| feature-151 | Natural variant | disease |
| feature-152 | Natural variant | disease |
| feature-153 | Natural variant | disease |
| feature-154 | Natural variant | disease |
| feature-155 | Natural variant | disease |
| feature-156 | Natural variant | disease |
| feature-157 | Natural variant | disease |
| feature-158 | Natural variant | disease |
| feature-159 | Natural variant | disease |
| feature-160 | Natural variant | disease |
| feature-161 | Natural variant | disease |
| feature-162 | Natural variant | disease |
| feature-163 | Natural variant | disease |
| feature-164 | Natural variant | disease |
| feature-165 | Natural variant | disease |
| feature-166 | Natural variant | disease |
| feature-167 | Natural variant | disease |
| feature-168 | Natural variant | disease |
| feature-169 | Natural variant | disease |
| feature-170 | Natural variant | disease |
| feature-171 | Natural variant | disease |
| feature-172 | Natural variant | disease |
| feature-173 | Natural variant | disease |
| feature-174 | Natural variant | disease |
| feature-175 | Natural variant | disease |
| feature-176 | Natural variant | disease |
| feature-177 | Natural variant | disease |
| feature-178 | Natural variant | disease |
| feature-179 | Natural variant | disease |
| feature-180 | Natural variant | disease |
| feature-181 | Natural variant | disease |
| feature-182 | Natural variant | disease |
| feature-183 | Natural variant | disease |
| feature-184 | Natural variant | disease |
| feature-185 | Natural variant | disease |
| feature-186 | Natural variant | disease |
| feature-187 | Natural variant | disease |
| feature-188 | Natural variant | disease |
| feature-189 | Natural variant | disease |
| feature-190 | Natural variant | disease |
| feature-191 | Natural variant | disease |
| feature-192 | Natural variant | disease |
| feature-193 | Natural variant | disease |
| feature-194 | Mutagenesis | disease |
| feature-195 | Mutagenesis | disease |
| feature-196 | Mutagenesis | disease |
| feature-197 | Mutagenesis | disease |
| feature-198 | Mutagenesis | disease |
| feature-199 | Mutagenesis | disease |
| feature-200 | Mutagenesis | disease |
| feature-201 | Mutagenesis | disease |
| feature-202 | Mutagenesis | disease |
| feature-203 | Mutagenesis | disease |
| feature-204 | Mutagenesis | disease |
| feature-205 | Mutagenesis | disease |
| feature-206 | Sequence conflict | sequence |
| feature-207 | Sequence conflict | sequence |
| feature-208 | Sequence conflict | sequence |
| feature-209 | Sequence conflict | sequence |
| feature-210 | Sequence conflict | sequence |
| feature-211 | Helix | sequence |
| feature-212 | Beta strand | sequence |
| feature-213 | Beta strand | sequence |
| feature-214 | Beta strand | sequence |
| feature-215 | Helix | sequence |
| feature-216 | Beta strand | sequence |
| feature-217 | Helix | sequence |
| feature-218 | Turn | sequence |
| feature-219 | Beta strand | sequence |
| feature-220 | Beta strand | sequence |
| feature-221 | Helix | sequence |
| feature-222 | Beta strand | sequence |
| feature-223 | Turn | sequence |
| feature-224 | Helix | sequence |